{"meta":{"page":1,"per_page":50,"max_per_page":100,"total":1136,"total_is_capped":false,"direct_labels_cover":0,"predictions_cover":1136,"direct_label_status":"direct model label, unvalidated","prediction_status":"machine_predicted_unvalidated (Codex and Gemma teacher distillation)","score_status":"score_only:v0-immature-baseline (scores rank; they never assert a category)","snapshot":{"source":"OpenAlex, pinned release, all 482 partitions","release":"2026-06-24","frame_built":"2026-07-12"},"query_hash":"7437e4e67cc8","filters":{"topic":"Chronic Myeloid Leukemia Treatments"}},"results":[{"id":"W2028959752","doi":"10.1056/nejmoa022457","title":"Imatinib Compared with Interferon and Low-Dose Cytarabine for Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia","year":2003,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":3565,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Vancouver General Hospital","funders":"","keywords":"Medicine; Imatinib; Cytarabine; Internal medicine; Gastroenterology; Myeloid leukemia; Imatinib mesylate; Confidence interval; Alpha interferon; Philadelphia chromosome; Immunology; Interferon; Oncology; Biology; Chromosomal translocation","retraction":null,"screen_n_in":null,"score":{"opus":0.0192848738368445,"gpt":0.2947119224179476,"spread":0.2754270485811031,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0008770572,0.0004738097,0.001341035,0.0003066809,0.0001065522,0.00002289046,0.0001694213,0.0001316244,0.0004694565],"category_scores_gemma":[0.0006379546,0.0002956387,0.0001270634,0.0002510118,0.0002871725,0.0001912039,0.00002386252,0.0005936662,0.000006230124],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.002626245,"about_ca_system_score_gemma":0.003502637,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0001332443,"about_ca_topic_score_gemma":0.0002184983,"domain_scores_codex":[0.9972774,0.0001224718,0.001042979,0.0003713261,0.0006243452,0.0005614731],"domain_scores_gemma":[0.9971455,0.0006275025,0.000674693,0.0004027458,0.0003255784,0.0008240051],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.04895031,0.001734399,0.007530162,0.003077164,0.003647862,0.005614429,0.007265734,0.001359486,0.1109995,0.000674122,0.05275628,0.7563905],"study_design_scores_gemma":[0.8264492,0.05184864,0.002632119,0.005664341,0.001779084,0.0105274,0.0004382881,0.002542373,0.008161654,0.0002327029,0.08924342,0.0004808176],"study_design_candidate":"randomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.977703,0.01257369,0.004387468,0.002902979,0.0005441486,0.001148334,0.00001274088,0.00003823496,0.0006893409],"genre_scores_gemma":[0.9899189,0.001594123,0.003500759,0.0003987623,0.003702181,0.00002260425,0.0000570552,0.00007790494,0.000727639],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.7774988,"threshold_uncertainty_score":0.9999496,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2107268345","doi":"10.1056/nejmoa062867","title":"Five-Year Follow-up of Patients Receiving Imatinib for Chronic Myeloid Leukemia","year":2006,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":3481,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Vancouver General Hospital","funders":"Celgene; Pfizer; Kementerian Pendidikan Nasional; Bristol-Myers Squibb; Amgen","keywords":"Medicine; Imatinib; Internal medicine; Cytarabine; Myeloid leukemia; Adverse effect; Imatinib mesylate; Philadelphia chromosome; Alpha interferon; Gastroenterology; Oncology; Surgery; Immunology; Interferon; Chromosomal translocation","retraction":null,"screen_n_in":null,"score":{"opus":0.01252982675583111,"gpt":0.2622417208740349,"spread":0.2497118941182038,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007191374,0.0002622369,0.0009696091,0.0002803459,0.00005628429,0.000006095961,0.000177656,0.0001236909,0.0003504762],"category_scores_gemma":[0.000892065,0.0001790077,0.000227743,0.0002211028,0.0001149364,0.0001212994,0.00002760438,0.0003343195,0.000006226049],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001451624,"about_ca_system_score_gemma":0.001392938,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0003625382,"about_ca_topic_score_gemma":0.0001150256,"domain_scores_codex":[0.9974374,0.00005987366,0.001175761,0.0002054987,0.0007579116,0.0003635819],"domain_scores_gemma":[0.9975077,0.0004533822,0.0009210857,0.0002848031,0.0005590448,0.0002739689],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.01417819,0.0006969522,0.1994035,0.001710544,0.001439026,0.0002463535,0.003365746,0.0004520055,0.02747731,0.0005131657,0.2378775,0.5126398],"study_design_scores_gemma":[0.658413,0.01407297,0.2271892,0.004159279,0.001749654,0.0005145994,0.0002585431,0.0004208402,0.007318108,0.001459013,0.0840723,0.0003724457],"study_design_candidate":"randomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9915723,0.001931573,0.0007383477,0.001308218,0.001181308,0.0005473123,0.00001678884,0.00001877591,0.002685401],"genre_scores_gemma":[0.9875211,0.0002995351,0.002992059,0.0001192751,0.005633996,0.000005135681,0.0000875651,0.00004775343,0.003293555],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.6442348,"threshold_uncertainty_score":0.7299722,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W1968747503","doi":"10.1182/blood-2013-05-501569","title":"European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013","year":2013,"lang":"en","type":"review","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":1989,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"National Institute for Health and Care Research","keywords":"Medicine; Myeloid leukemia; Internal medicine; Intensive care medicine","retraction":null,"screen_n_in":null,"score":{"opus":0.05498044835877869,"gpt":0.3203154554899036,"spread":0.265335007131125,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0004429266,0.0006597318,0.00166462,0.0001737974,0.0001687015,0.00003663504,0.0006268219,0.000250303,0.0006903856],"category_scores_gemma":[0.00002139492,0.0004172791,0.0008758745,0.0003335213,0.0001208128,0.00006647246,0.0002796511,0.0005335509,0.0008798081],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.002509714,"about_ca_system_score_gemma":0.001407842,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0001190313,"about_ca_topic_score_gemma":0.00001113784,"domain_scores_codex":[0.9971624,0.0001594818,0.001135028,0.0006516813,0.0003331801,0.000558229],"domain_scores_gemma":[0.9969982,0.0003891516,0.0007480386,0.001588829,0.0001120669,0.0001637108],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.000004808232,0.000294463,0.000001004339,0.0317237,0.004581503,0.00003537694,0.00002583744,0.000001478086,7.959319e-7,0.0001786351,0.04997561,0.9131768],"study_design_scores_gemma":[0.004696822,0.0003046542,0.0000126954,0.01713558,0.01864356,0.0001768339,0.00003482892,0.00001785406,0.000008790918,0.00001011431,0.9586474,0.0003109274],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.00000921522,0.9847025,0.0001069177,0.0003038865,0.0003924824,0.006342559,0.0002645922,0.00009427352,0.007783609],"genre_scores_gemma":[0.000008552712,0.9797863,0.003331107,0.00005726417,0.0006996775,0.001586917,0.001406245,0.0002022718,0.01292163],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.9128659,"threshold_uncertainty_score":0.9998981,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W3009751715","doi":"10.1038/s41375-020-0776-2","title":"European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia","year":2020,"lang":"en","type":"review","venue":"Leukemia","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":1510,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"University of Toronto","funders":"Daiichi Sankyo Europe; Scheme for Promotion of Academic and Research Collaboration; Sun Pharma; Servier; Astellas Pharma; Incyte; Italfarmaco; Seagen; Agios Pharmaceuticals; Astex Pharmaceuticals; Celgene; Daiichi-Sankyo; National Institute for Health and Care Research; Teva Pharmaceutical Industries; Gilead Sciences; Ariad Pharmaceuticals; Amgen; Pfizer; Ascentage Pharma","keywords":"Medicine; Dasatinib; Nilotinib; Bosutinib; Discontinuation; Imatinib; Myeloid leukemia; Tyrosine-kinase inhibitor; Internal medicine; Oncology; Intensive care medicine","retraction":null,"screen_n_in":null,"score":{"opus":0.04811984751068918,"gpt":0.3335786658783663,"spread":0.2854588183676771,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["metaepi_narrow","insufficient_payload"],"category_scores_codex":[0.0006163816,0.002006306,0.005048637,0.0004206924,0.0005140917,0.0001921342,0.0009845461,0.0009501692,0.0009842302],"category_scores_gemma":[0.00064773,0.001792925,0.002362353,0.001213002,0.0001980659,0.00023839,0.000462452,0.002183887,0.00317014],"about_ca_system_candidate":true,"about_ca_system_consensus":true,"about_ca_system_score_codex":0.06540783,"about_ca_system_score_gemma":0.02233397,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000173426,"about_ca_topic_score_gemma":0.00004545317,"domain_scores_codex":[0.9923265,0.0005416499,0.002532126,0.002343633,0.0006770897,0.001579008],"domain_scores_gemma":[0.9943925,0.0009825489,0.001452723,0.001935206,0.0001949013,0.001042112],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.00005507133,0.00004443162,0.000002638267,0.02005261,0.001289832,0.0005461125,0.000144761,0.000008845145,0.00001238638,0.00008992318,0.1092763,0.868477],"study_design_scores_gemma":[0.005591969,0.0007023793,0.000005935927,0.021949,0.006536294,0.001323955,0.00004505554,0.000423934,0.00002357746,0.00002112533,0.9620646,0.001312216],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.00001489467,0.9722241,0.0003072627,0.0006631429,0.0008841562,0.005604379,0.0009621062,0.0008580058,0.01848196],"genre_scores_gemma":[0.00002543741,0.9618719,0.006488719,0.0006299658,0.005634998,0.001220149,0.01174417,0.0008703353,0.01151431],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.8671649,"threshold_uncertainty_score":0.999929,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2012962381","doi":"10.1056/nejmoa040258","title":"Granulocyte–Macrophage Progenitors as Candidate Leukemic Stem Cells in Blast-Crisis CML","year":2004,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":1489,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"University of Toronto","funders":"National Institute of Allergy and Infectious Diseases; National Cancer Institute; National Heart, Lung, and Blood Institute","keywords":"Chronic myelogenous leukemia; Stem cell; Blast Crisis; Haematopoiesis; Progenitor cell; Medicine; Cancer research; Leukemia; Immunology; Cell biology; Biology","retraction":null,"screen_n_in":null,"score":{"opus":0.01126369969363871,"gpt":0.2634698004514213,"spread":0.2522061007577825,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007575633,0.0003438749,0.0009599312,0.0005242464,0.00005364314,0.00001205954,0.0002159057,0.0001507137,0.0002548049],"category_scores_gemma":[0.0001071292,0.0002300382,0.0001525198,0.0004673683,0.0001238809,0.0001359972,0.00003324752,0.0008101178,0.00007321334],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.002153429,"about_ca_system_score_gemma":0.002048428,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002274777,"about_ca_topic_score_gemma":0.0002457598,"domain_scores_codex":[0.9971887,0.00009818956,0.001038849,0.0002793802,0.0009081342,0.0004866922],"domain_scores_gemma":[0.9981765,0.0001202429,0.0004551258,0.0003315404,0.0001711056,0.0007454935],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.01993927,0.001908972,0.05705903,0.001083181,0.00239667,0.07418145,0.0245703,0.003041115,0.2694018,0.0002275951,0.04472345,0.5014672],"study_design_scores_gemma":[0.6731023,0.01303133,0.008976895,0.004790014,0.001871352,0.02903491,0.002380958,0.00006081959,0.2064378,0.001421086,0.05819354,0.0006989927],"study_design_candidate":"randomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9889012,0.003984184,0.0000999812,0.004796507,0.001018702,0.0004014566,0.000004498469,0.00002554139,0.0007679405],"genre_scores_gemma":[0.9930159,0.001540372,0.0004446542,0.0006884994,0.003081684,0.000003988244,0.000007562606,0.00004941729,0.001167951],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.653163,"threshold_uncertainty_score":0.9380684,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2148743957","doi":"10.1182/blood-2006-01-0092","title":"Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results","year":2006,"lang":"en","type":"review","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":1202,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"Fogarty International Center; European Commission","keywords":"Imatinib mesylate; Tyrosine kinase; Philadelphia chromosome; Fluorescence in situ hybridization; Imatinib; ABL; Myeloid leukemia; Cancer research; Medicine; breakpoint cluster region; Tyrosine-kinase inhibitor; Internal medicine; Oncology; Biology; Bioinformatics; Gene; Genetics; Cancer; Chromosomal translocation; Chromosome; Receptor","retraction":null,"screen_n_in":null,"score":{"opus":0.1864627210656154,"gpt":0.4071127916725872,"spread":0.2206500706069719,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0007879431,0.0006964508,0.00201441,0.0006126213,0.0005675764,0.00009080307,0.00006861505,0.0001999117,6.384407e-7],"category_scores_gemma":[0.0009810688,0.0005527577,0.0002453003,0.0004059995,0.00006236872,0.0001419425,0.00004653415,0.0001951124,2.012911e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000677965,"about_ca_system_score_gemma":0.0002934647,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00003513545,"about_ca_topic_score_gemma":0.00001937552,"domain_scores_codex":[0.9968474,0.0002624209,0.001114802,0.001066397,0.0001492821,0.0005596822],"domain_scores_gemma":[0.9958232,0.002720485,0.0005932058,0.0003546423,0.0002206759,0.0002877803],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0003283917,0.0004239695,0.00008576111,0.03606408,0.0004049363,0.000006674516,0.0005946162,1.955813e-7,0.0001345717,0.00001018101,0.00008868429,0.9618579],"study_design_scores_gemma":[0.03312887,0.003812048,0.00005091381,0.1654183,0.02512197,0.0001584257,0.0002005833,0.000006959165,0.001809721,0.00006515926,0.7693691,0.0008580156],"study_design_candidate":"design_other","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.006484784,0.9765157,0.002977403,0.0002983974,0.0002436066,0.01174942,0.001662823,0.00006239017,0.000005520863],"genre_scores_gemma":[0.0002407219,0.7922041,0.19941,0.00002572305,0.0003863028,0.006220387,0.001316632,0.0001428876,0.00005322278],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.9609999,"threshold_uncertainty_score":0.9996924,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2096336184","doi":"10.1200/jco.2008.21.2514","title":"Improved Early Event-Free Survival With Imatinib in Philadelphia Chromosome–Positive Acute Lymphoblastic Leukemia: A Children's Oncology Group Study","year":2009,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":709,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"BC Children's Hospital","funders":"National Cancer Institute","keywords":"Medicine; Imatinib; Lymphoblastic Leukemia; Oncology; Internal medicine; Philadelphia chromosome; Leukemia; Chromosomal translocation; Genetics; Gene; Myeloid leukemia","retraction":null,"screen_n_in":null,"score":{"opus":0.03415208848965093,"gpt":0.3877666745477761,"spread":0.3536145860581252,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.003406202,0.0005126811,0.003816995,0.0003981552,0.00008110122,0.0000225566,0.0006479219,0.0008566923,0.0001100056],"category_scores_gemma":[0.002356053,0.0003567081,0.0005993894,0.0005428406,0.0003526302,0.0003122435,0.0001694567,0.002538146,0.00002510504],"about_ca_system_candidate":true,"about_ca_system_consensus":true,"about_ca_system_score_codex":0.005920832,"about_ca_system_score_gemma":0.009032023,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0002386775,"about_ca_topic_score_gemma":0.00062488,"domain_scores_codex":[0.9923785,0.001275961,0.004056774,0.0006556971,0.0008608755,0.0007721967],"domain_scores_gemma":[0.9921705,0.00285632,0.002995433,0.000713003,0.0004954817,0.0007693375],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.1134802,0.06531145,0.5642493,0.0000530137,0.01213343,0.05079226,0.002880318,0.0002029023,0.002386475,0.0001874366,0.002147044,0.1861761],"study_design_scores_gemma":[0.09075719,0.1757483,0.7272879,0.0001990711,0.001817915,0.003092989,0.000272841,0.0002098517,0.00003657754,0.0001753833,0.0001569766,0.000244956],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9903781,0.0001979417,0.0001930868,0.005847805,0.0008625995,0.001487189,0.00002044399,0.00003356267,0.0009793011],"genre_scores_gemma":[0.9934244,0.0002409235,0.003203279,0.001530129,0.001420054,0.00002472617,0.00001710089,0.00005140148,0.00008797319],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1859312,"threshold_uncertainty_score":0.9998885,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2080125373","doi":"10.1182/blood-2006-09-047266","title":"Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy","year":2006,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":609,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Princess Margaret Cancer Centre","funders":"Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Dasatinib; Imatinib; Medicine; Myeloid leukemia; Internal medicine; Imatinib mesylate; Adverse effect; Nilotinib; Oncology; Pharmacology; Gastroenterology; Immunology","retraction":null,"screen_n_in":null,"score":{"opus":0.01723478757040318,"gpt":0.2844798465666158,"spread":0.2672450589962126,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0002336463,0.0003774775,0.0007362583,0.0002602366,0.00005491332,0.00002344902,0.0001406228,0.0002545644,0.0003426019],"category_scores_gemma":[0.00006930067,0.0003111504,0.0001061872,0.0003652066,0.0002203146,0.0001112344,0.00007863292,0.0002801833,0.00002377334],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001118945,"about_ca_system_score_gemma":0.001859979,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0005395989,"about_ca_topic_score_gemma":0.0005540465,"domain_scores_codex":[0.9977732,0.000122732,0.0006811885,0.0005451856,0.0003351123,0.0005425903],"domain_scores_gemma":[0.9988078,0.0002025252,0.0002306415,0.0005850942,0.00006391142,0.0001100304],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.001918414,0.002429188,0.1291461,0.0009313326,0.0003478155,0.0009938875,0.0006287465,0.00005500995,0.8540903,0.0001120141,0.0002680136,0.009079174],"study_design_scores_gemma":[0.06290635,0.003038892,0.2171823,0.0007672953,0.0002753235,0.0007217343,0.0001101203,0.000158515,0.7129069,0.0001958527,0.001268848,0.0004678828],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9766186,0.02169566,0.000005520323,0.0001821093,0.00003207509,0.0009288102,0.00004545851,0.00006402397,0.0004277764],"genre_scores_gemma":[0.9967502,0.0007576428,0.001551797,0.0000655658,0.0001751549,0.0002350722,0.00005543488,0.00005232203,0.000356794],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1411834,"threshold_uncertainty_score":0.9999341,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2528188718","doi":"10.1200/jco.2016.68.2914","title":"Long-Term Follow-Up of the French Stop Imatinib (STIM1) Study in Patients With Chronic Myeloid Leukemia","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":494,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Hôpital Saint-François d'Assise","funders":"","keywords":"Medicine; Discontinuation; Imatinib; Myeloid leukemia; Internal medicine; Surgery; Imatinib mesylate; Minimal residual disease; Population; Gastroenterology; Leukemia","retraction":null,"screen_n_in":null,"score":{"opus":0.0484770343475114,"gpt":0.3846886422397793,"spread":0.3362116078922679,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001961849,0.0002439667,0.00183688,0.0001503039,0.00003692599,0.000004706883,0.0004357244,0.0003256677,0.0003249554],"category_scores_gemma":[0.002472494,0.0001063679,0.000431343,0.0002512564,0.0003656859,0.0001438586,0.0001524563,0.0009050648,0.00002296493],"about_ca_system_candidate":true,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.003687599,"about_ca_system_score_gemma":0.008302898,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00008376675,"about_ca_topic_score_gemma":0.0009278092,"domain_scores_codex":[0.9949663,0.000624708,0.002913398,0.0002985343,0.0008274415,0.0003695681],"domain_scores_gemma":[0.994038,0.001906555,0.002683359,0.0005947684,0.0005064399,0.0002708057],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.003353508,0.003006061,0.887028,0.00003240398,0.0005348623,0.0001966277,0.0001764607,0.00000627813,0.00004341351,0.000003601662,0.0004643743,0.1051544],"study_design_scores_gemma":[0.08819403,0.02899511,0.8810015,0.0006378419,0.0005116116,0.00005293372,0.00002835317,0.00000520412,0.00007295146,0.00002561896,0.0003740266,0.0001008383],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9962971,0.000150935,0.00003017639,0.0008643569,0.0012417,0.0009025984,0.000006189272,0.000007082322,0.000499893],"genre_scores_gemma":[0.9980555,0.00008121226,0.0003239863,0.0002069207,0.0004324276,0.00001101344,0.000001574608,0.00002900007,0.0008584196],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1050536,"threshold_uncertainty_score":0.9973191,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W1981083415","doi":"10.1016/j.ccr.2005.10.015","title":"The tumor suppressor PP2A is functionally inactivated in blast crisis CML through the inhibitory activity of the BCR/ABL-regulated SET protein","year":2005,"lang":"en","type":"article","venue":"Cancer Cell","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":472,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Université de Montréal; Hôpital Maisonneuve-Rosemont","funders":"National Institutes of Health; National Cancer Institute; University of Pennsylvania","keywords":"Chronic myelogenous leukemia; Cancer research; Protein phosphatase 2; breakpoint cluster region; Progenitor cell; Imatinib mesylate; ABL; Biology; Imatinib; Leukemia; Stem cell; Cell biology; Phosphorylation; Immunology; Signal transduction; Phosphatase; Myeloid leukemia; Tyrosine kinase; Receptor; Genetics","retraction":null,"screen_n_in":null,"score":{"opus":0.01474678763094991,"gpt":0.2611239385216091,"spread":0.2463771508906592,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002013846,0.0002651,0.0003153073,0.00002597039,0.0002256702,0.00002083001,0.0002960416,0.0001150521,0.0007000873],"category_scores_gemma":[0.00005065041,0.000132283,0.0001564398,0.0003298351,0.0002510988,0.0001834778,0.0001329905,0.0004793177,0.00002609262],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.002327437,"about_ca_system_score_gemma":0.000973194,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.003710965,"about_ca_topic_score_gemma":0.001728471,"domain_scores_codex":[0.9981952,0.0001808703,0.0003503361,0.0003691226,0.0005098594,0.0003945767],"domain_scores_gemma":[0.9985228,0.0001598504,0.0002806368,0.0008341637,0.0001426982,0.00005983137],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.00398245,0.00150371,0.006989636,0.0004644763,0.0008196562,0.00002913779,0.008793907,0.001567953,0.8257056,0.0001365651,0.1430647,0.006942251],"study_design_scores_gemma":[0.003795061,0.000111177,0.01974518,0.0002245006,0.0001303526,0.00001052492,0.0007310408,0.0004715726,0.9058111,0.00005280842,0.06876132,0.0001553399],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.983938,0.001247768,0.000004846407,0.009876699,0.0002518135,0.001504168,0.00008066146,0.00003520232,0.00306087],"genre_scores_gemma":[0.993412,0.00009146021,0.00002859396,0.0009357337,0.000282056,0.000362838,0.000008785242,0.00004104405,0.004837518],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.08010555,"threshold_uncertainty_score":0.7665465,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2004492241","doi":"10.1182/blood-2006-09-046839","title":"Dasatinib induces significant hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in accelerated phase","year":2007,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":372,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Dasatinib; Imatinib; Medicine; Internal medicine; Neutropenia; Myeloid leukemia; Adverse effect; Imatinib mesylate; Nilotinib; Gastroenterology; Oncology; Chemotherapy","retraction":null,"screen_n_in":null,"score":{"opus":0.02939114940907976,"gpt":0.3000116606126729,"spread":0.2706205112035932,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0004928791,0.0004233515,0.0007574047,0.0004701993,0.00007269709,0.00003583057,0.000145794,0.0002030313,0.0001323133],"category_scores_gemma":[0.000261179,0.0002894327,0.00004102036,0.0008098349,0.0001622827,0.0001084818,0.00006784189,0.0003766608,0.00001322028],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001798475,"about_ca_system_score_gemma":0.001862166,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0003158497,"about_ca_topic_score_gemma":0.0008100308,"domain_scores_codex":[0.9971616,0.0001281165,0.0008425695,0.0006733852,0.0004611652,0.0007331516],"domain_scores_gemma":[0.9986202,0.0003580387,0.0002392997,0.0004541125,0.00009278445,0.0002355808],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.03304048,0.00723517,0.812323,0.00071702,0.0003872999,0.006109823,0.00202588,0.00002609277,0.1238138,0.00002717205,0.00003054447,0.01426367],"study_design_scores_gemma":[0.08733264,0.005205348,0.8171641,0.0008012248,0.0001946198,0.0001219158,0.0003048307,0.00008332213,0.08833933,0.00001076127,0.00004230999,0.0003995666],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9973195,0.0006914541,0.000008637828,0.00004741987,0.00003213684,0.001576095,0.00003112025,0.00007181914,0.0002218775],"genre_scores_gemma":[0.998264,0.00009029679,0.001209904,0.00008795743,0.00003793128,0.00009122861,0.00007986511,0.00005223544,0.00008658025],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.05429216,"threshold_uncertainty_score":0.9999558,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2152713204","doi":"10.1158/0008-5472.can-06-1199","title":"<i>In vitro</i> and <i>In vivo</i> Activity of SKI-606, a Novel Src-Abl Inhibitor, against Imatinib-Resistant Bcr-Abl+ Neoplastic Cells","year":2006,"lang":"en","type":"article","venue":"Cancer Research","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":371,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"McGill University; Jewish General Hospital","funders":"","keywords":"Imatinib; Chronic myelogenous leukemia; ABL; Cancer research; Imatinib mesylate; In vivo; Leukemia; Biology; breakpoint cluster region; Pharmacology; Receptor; Immunology; Tyrosine kinase; Genetics","retraction":null,"screen_n_in":null,"score":{"opus":0.02715129866584341,"gpt":0.3319171761275068,"spread":0.3047658774616633,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0008034477,0.000288206,0.0006810852,0.0005020916,0.00008256869,0.0000384256,0.0001752945,0.0001868868,0.0001424036],"category_scores_gemma":[0.0001439716,0.0002655186,0.00008533669,0.0009940566,0.0003711502,0.0001760843,0.0001830815,0.0007724139,0.00001791721],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00255734,"about_ca_system_score_gemma":0.001570095,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00994586,"about_ca_topic_score_gemma":0.002380141,"domain_scores_codex":[0.9967005,0.0001624338,0.0005227629,0.0006714004,0.0009914949,0.0009514545],"domain_scores_gemma":[0.9983295,0.0006167807,0.0001210405,0.0005239471,0.0001891241,0.0002196344],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.002560541,0.0008101166,0.001845284,0.0006495215,0.00003452117,0.0002420226,0.0001830552,0.0001226496,0.9893593,0.00002715852,0.003058886,0.00110693],"study_design_scores_gemma":[0.01038718,0.0002417967,0.00506246,0.0007959876,0.00002847448,0.00001274174,0.00008274164,0.000744498,0.977771,0.0000513255,0.004600184,0.0002215881],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9924586,0.001394446,0.00001627333,0.0005567924,0.0001550344,0.001075379,0.0002232944,0.00002302765,0.004097114],"genre_scores_gemma":[0.9963371,0.0004123765,0.0003581838,0.000107055,0.0002434453,0.0002473629,0.00001311338,0.00005829627,0.002223073],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.01158829,"threshold_uncertainty_score":0.9999797,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2140351909","doi":"10.1016/j.ccr.2014.07.006","title":"BCR-ABL1 Compound Mutations Combining Key Kinase Domain Positions Confer Clinical Resistance to Ponatinib in Ph Chromosome-Positive Leukemia","year":2014,"lang":"en","type":"article","venue":"Cancer Cell","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":366,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"National Cancer Institute; National Institutes of Health; National Heart, Lung, and Blood Institute; Huntsman Cancer Institute; University of Utah; American Society of Hematology; Leukemia and Lymphoma Society; Office of Science; Imperial College London; Howard Hughes Medical Institute","keywords":"Ponatinib; Cancer research; Protein kinase domain; Leukemia; ABL; Mutation; Biology; Philadelphia chromosome; breakpoint cluster region; Drug resistance; Kinase; Myeloid leukemia; Genetics; Tyrosine kinase; Dasatinib; Chromosomal translocation; Imatinib; Signal transduction; Gene; Mutant","retraction":null,"screen_n_in":null,"score":{"opus":0.0224330624772539,"gpt":0.3231792071203803,"spread":0.3007461446431264,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0003834332,0.0003010957,0.0006225429,0.000131315,0.0001741577,0.00004277236,0.000176355,0.0001793963,0.000636076],"category_scores_gemma":[0.0001378492,0.0003102034,0.0001460507,0.0003803661,0.0001950279,0.0001317714,0.00007346892,0.0004469631,0.0002248122],"about_ca_system_candidate":true,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.004533569,"about_ca_system_score_gemma":0.001277298,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000888782,"about_ca_topic_score_gemma":0.003074065,"domain_scores_codex":[0.9975567,0.0002383164,0.000703197,0.0006500217,0.0003424964,0.0005092879],"domain_scores_gemma":[0.9978932,0.0007558391,0.000177207,0.0005350781,0.0002190676,0.0004196309],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.01557983,0.01690965,0.323923,0.003300888,0.003293684,0.008009635,0.08898454,0.00598992,0.2150075,0.05990543,0.2063256,0.05277038],"study_design_scores_gemma":[0.1120117,0.003342644,0.6082677,0.007520965,0.001571122,0.0001779806,0.005144156,0.004298572,0.05610014,0.005646344,0.1925568,0.003361867],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9368464,0.0008028251,0.0006050898,0.001646247,0.0004571094,0.0009460779,0.0002134126,0.00008748427,0.05839538],"genre_scores_gemma":[0.989728,0.0001128141,0.004249802,0.002470291,0.0003300863,0.0002654514,0.0003614837,0.00006034596,0.002421702],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.2843447,"threshold_uncertainty_score":0.999935,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2112127173","doi":"10.1084/jem.191.6.977","title":"Blockade of the Bcr-Abl Kinase Activity Induces Apoptosis of Chronic Myelogenous Leukemia Cells by Suppressing Signal Transducer and Activator of Transcription 5–Dependent Expression of Bcl-XL","year":2000,"lang":"en","type":"article","venue":"The Journal of Experimental Medicine","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":364,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false},"ca_institutions":"","funders":"University of Toronto; University of Minnesota","keywords":"Chronic myelogenous leukemia; STAT protein; STAT5; breakpoint cluster region; Cancer research; ABL; K562 cells; Signal transduction; Apoptosis; Biology; Kinase; Leukemia; STAT3; Cell biology; Tyrosine kinase; Immunology; Receptor","retraction":null,"screen_n_in":null,"score":{"opus":0.0144349625745394,"gpt":0.2611755670376567,"spread":0.2467406044631173,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000538045,0.0002861127,0.0009553205,0.0001242124,0.00008242665,0.000002617618,0.0002934482,0.0001480522,0.0009396052],"category_scores_gemma":[0.00002210239,0.0001536926,0.0001989746,0.0001968518,0.000749366,0.0001692586,0.00003363684,0.0004161967,2.684757e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006883201,"about_ca_system_score_gemma":0.0004287135,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0004693627,"about_ca_topic_score_gemma":0.000002957712,"domain_scores_codex":[0.997274,0.0003080757,0.0009994141,0.0001805669,0.0009905299,0.0002474461],"domain_scores_gemma":[0.9981169,0.0002146423,0.00104207,0.0003693537,0.0001092589,0.0001478406],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.003270398,0.0009736537,0.0001050332,0.0002745353,0.0002630599,0.000004233119,0.00835678,0.00006113097,0.9783472,6.016877e-7,0.0001661571,0.00817724],"study_design_scores_gemma":[0.008929564,0.003471089,0.001017703,0.002397993,0.0006781349,0.000144344,0.002375546,0.00005394006,0.9807823,0.000006675615,0.00004236737,0.0001003967],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9867694,0.0120617,0.0000328223,0.0003010392,0.000160892,0.0004879028,0.00003328616,0.000004406998,0.0001484813],"genre_scores_gemma":[0.998392,0.001210244,0.00008206133,0.0000266543,0.0001626067,0.000004793523,0.000003217394,0.00002941714,0.00008896094],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.01162258,"threshold_uncertainty_score":0.9999737,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2012153991","doi":"10.1038/sj.leu.2404609","title":"Chronic myeloid leukemia stem cells possess multiple unique features of resistance to BCR-ABL targeted therapies","year":2007,"lang":"en","type":"article","venue":"Leukemia","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":358,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"University of British Columbia; Terry Fox Research Institute; BC Cancer Agency","funders":"","keywords":"CD38; Imatinib mesylate; Myeloid leukemia; Stem cell; Haematopoiesis; Cancer research; Biology; CD34; Myeloid; breakpoint cluster region; Leukemia; Imatinib; Immunology; Cell biology; Receptor; Genetics","retraction":null,"screen_n_in":null,"score":{"opus":0.01218732001443293,"gpt":0.2583148605492473,"spread":0.2461275405348144,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0007028898,0.0006517421,0.001023209,0.0003937408,0.000174016,0.00004132374,0.0005490136,0.0004720276,0.0002044721],"category_scores_gemma":[0.0001027455,0.0005784337,0.0003080234,0.0009419277,0.0002266442,0.0001759388,0.0002232723,0.0006991511,0.0001431706],"about_ca_system_candidate":true,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.01633129,"about_ca_system_score_gemma":0.003565636,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001023731,"about_ca_topic_score_gemma":0.002101542,"domain_scores_codex":[0.9960026,0.0001148636,0.0009459892,0.0008974338,0.000900808,0.001138333],"domain_scores_gemma":[0.9968264,0.0005161409,0.0003774353,0.00140549,0.0003393861,0.0005351189],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.002651391,0.000184284,0.006975203,0.001113267,0.0007836258,0.0006361609,0.003475689,0.000547802,0.9255753,0.0006555847,0.0221893,0.03521243],"study_design_scores_gemma":[0.007052118,0.0006230792,0.06001464,0.0007790599,0.0001780664,0.00006704868,0.0006852782,0.00006251096,0.8931037,0.0001028973,0.03673928,0.0005923291],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9806381,0.007542918,0.0008150103,0.0004141442,0.0005178191,0.001784714,0.00009549234,0.0003439856,0.007847806],"genre_scores_gemma":[0.9699125,0.0003080189,0.006044204,0.0006018627,0.0004496383,0.00007397478,0.00007819103,0.0001489406,0.02238264],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.05303943,"threshold_uncertainty_score":0.9996667,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W1990020715","doi":"10.1038/leu.2008.84","title":"Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib","year":2008,"lang":"en","type":"article","venue":"Leukemia","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":354,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Dasatinib; Medicine; Imatinib; Chronic myelogenous leukemia; Internal medicine; Gastroenterology; Neutropenia; Imatinib mesylate; Leukemia; Oncology; Chemotherapy; Myeloid leukemia","retraction":null,"screen_n_in":null,"score":{"opus":0.02218488206773787,"gpt":0.2795651517636827,"spread":0.2573802696959449,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0002927289,0.0007821849,0.001194797,0.0006485727,0.0002267891,0.00003737899,0.0004446103,0.0002918322,0.0002551586],"category_scores_gemma":[0.0002308002,0.0005807923,0.00007777153,0.001984326,0.0003386978,0.000302646,0.0001079095,0.0008288924,0.0001451407],"about_ca_system_candidate":true,"about_ca_system_consensus":true,"about_ca_system_score_codex":0.0498163,"about_ca_system_score_gemma":0.02106473,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001511332,"about_ca_topic_score_gemma":0.01588229,"domain_scores_codex":[0.9951293,0.0002026025,0.001020871,0.001284744,0.0009952936,0.001367209],"domain_scores_gemma":[0.9974329,0.0002743134,0.000339398,0.001320961,0.0001990906,0.0004332667],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.1356671,0.002358692,0.7639591,0.002307049,0.0007172332,0.0135586,0.0128595,0.01965971,0.02420533,0.00004948822,0.002546641,0.0221115],"study_design_scores_gemma":[0.09871811,0.01114966,0.8609933,0.004171972,0.0001386833,0.0003550293,0.0001532502,0.0005484587,0.01937132,0.00001316407,0.003122435,0.00126462],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9944185,0.001202267,0.00004533644,0.0001589529,0.00007591945,0.002917719,0.00005784352,0.00014279,0.0009806454],"genre_scores_gemma":[0.990761,0.0002288912,0.003957496,0.0004106836,0.0001674616,0.0006383552,0.0001247041,0.0001622736,0.003549082],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.09703418,"threshold_uncertainty_score":0.9996644,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W3195243079","doi":"10.1182/blood.2020009984","title":"A phase 3, open-label, randomized study of asciminib, a STAMP inhibitor, vs bosutinib in CML after 2 or more prior TKIs","year":2021,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":336,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"National Cancer Institute; National Institute for Health and Care Research; Novartis Pharmaceuticals Corporation","keywords":"Bosutinib; Medicine; Open label; Randomized controlled trial; Internal medicine; Oncology; Imatinib; Nilotinib; Myeloid leukemia","retraction":null,"screen_n_in":null,"score":{"opus":0.0352400247850263,"gpt":0.3536891511236019,"spread":0.3184491263385756,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006070934,0.0003203558,0.001597371,0.0001694469,0.00004064462,0.00004284237,0.0002121075,0.0001311426,0.0008554183],"category_scores_gemma":[0.0009251711,0.0002371101,0.0001086339,0.0005865959,0.0001003407,0.0001272454,0.0003623424,0.0002684067,0.00002656968],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002362659,"about_ca_system_score_gemma":0.001501084,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0003501911,"about_ca_topic_score_gemma":0.0005977339,"domain_scores_codex":[0.9971765,0.0003376385,0.0009255653,0.0006285182,0.0005285814,0.0004032497],"domain_scores_gemma":[0.9982042,0.0003664705,0.0002202443,0.0008453028,0.0001722171,0.000191565],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.621223,0.2900729,0.02274021,0.000684923,0.003478668,0.02224615,0.02206869,0.000001401676,0.008388957,0.00001435834,0.0009599354,0.0081208],"study_design_scores_gemma":[0.9719812,0.004161485,0.001829358,0.0005697506,0.001610416,0.0001803802,0.001920927,0.00005198468,0.01696981,0.000009289644,0.0004890031,0.0002264443],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9936412,0.0009515165,0.000002708528,0.0003723119,0.0001229841,0.004271991,0.00004852101,0.00003794309,0.0005508431],"genre_scores_gemma":[0.9945101,0.00008954946,0.001560471,0.0003124327,0.000103819,0.0009514364,0.00004950981,0.00005461002,0.002368127],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.3507582,"threshold_uncertainty_score":0.9669071,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W1975748957","doi":"10.1172/jci31095","title":"FTY720, a new alternative for treating blast crisis chronic myelogenous leukemia and Philadelphia chromosome–positive acute lymphocytic leukemia","year":2007,"lang":"en","type":"article","venue":"Journal of Clinical Investigation","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":332,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false},"ca_institutions":"Université de Montréal; Hôpital Maisonneuve-Rosemont","funders":"National Cancer Institute; D. Warren Brown Family Foundation; Associazione Italiana per la Ricerca sul Cancro; Fonds de Recherche du Québec - Santé; Ministero della Salute; Ohio State University; American-Italian Cancer Foundation","keywords":"Chronic myelogenous leukemia; Cancer research; Philadelphia chromosome; Leukemia; Dasatinib; Progenitor cell; Medicine; Myeloid leukemia; Immunology; Imatinib; Stem cell; Biology","retraction":null,"screen_n_in":null,"score":{"opus":0.05296610249043909,"gpt":0.3724998987889664,"spread":0.3195337962985273,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.001972842,0.0003974268,0.001235235,0.0003017836,0.0001744312,0.00005864014,0.0001913819,0.0004062343,0.0000396439],"category_scores_gemma":[0.001683716,0.0003284567,0.0005050038,0.0003352502,0.0003484459,0.0004257705,0.00006512363,0.0006926815,0.00001449258],"about_ca_system_candidate":true,"about_ca_system_consensus":true,"about_ca_system_score_codex":0.0139057,"about_ca_system_score_gemma":0.01214434,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0003360154,"about_ca_topic_score_gemma":0.00005452785,"domain_scores_codex":[0.9956713,0.0001374466,0.002513037,0.0004925149,0.0006430841,0.0005425667],"domain_scores_gemma":[0.9941901,0.001825123,0.002025658,0.0002991658,0.0006019193,0.001058016],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"observational","study_design_scores_codex":[0.04054088,0.001385594,0.08851001,0.002501062,0.0332645,0.01010501,0.02375718,0.01027811,0.1885652,0.002633724,0.06352028,0.5349385],"study_design_scores_gemma":[0.2262997,0.04791682,0.2762373,0.009210135,0.01993402,0.023964,0.002620431,0.09475636,0.2671276,0.02365403,0.005431491,0.00284803],"study_design_candidate":"design_other","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9885501,0.001058587,0.006964816,0.001778597,0.0006035442,0.0007935711,0.0000251104,0.00004122284,0.0001844258],"genre_scores_gemma":[0.9751416,0.0008040384,0.01790891,0.001320332,0.00435867,0.000009968781,0.00005756444,0.00007207588,0.0003268616],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.5320904,"threshold_uncertainty_score":0.9999167,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2119584141","doi":"10.1016/j.jtbi.2005.03.033","title":"A mathematical model of hematopoiesis—I. Periodic chronic myelogenous leukemia","year":2005,"lang":"en","type":"article","venue":"Journal of Theoretical Biology","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":276,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false},"ca_institutions":"McGill University","funders":"Natural Sciences and Engineering Research Council of Canada; Mitacs","keywords":"Haematopoiesis; Chronic myelogenous leukemia; Stem cell; Leukemia; Biology; Hematopoietic stem cell; Immunology; Platelet; Cell biology; Cancer research","retraction":null,"screen_n_in":null,"score":{"opus":0.01444154634903463,"gpt":0.2819608383042284,"spread":0.2675192919551937,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0005237653,0.0002138465,0.0009548282,0.000165646,0.00003770049,0.000005854923,0.0002443212,0.0002806993,0.001717699],"category_scores_gemma":[0.0004764925,0.000140082,0.0003910157,0.0001066184,0.001102831,0.00004756057,0.0000826154,0.0004331926,0.00009108865],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001488576,"about_ca_system_score_gemma":0.001427347,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000001063985,"about_ca_topic_score_gemma":7.024867e-7,"domain_scores_codex":[0.9980897,0.00009634882,0.0009808603,0.0001806974,0.0002620399,0.0003903671],"domain_scores_gemma":[0.9985706,0.0002371616,0.0003823679,0.0003491352,0.0001998321,0.0002608954],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"theoretical_or_conceptual","study_design_scores_codex":[0.001221956,0.0007764117,0.0005695333,0.0003418812,0.0007276897,0.0001217951,0.0007794001,0.0006430469,0.1384145,0.8437656,0.0006448254,0.01199339],"study_design_scores_gemma":[0.0268359,0.01400721,0.0005537898,0.001522305,0.002967373,0.02130634,0.0004418992,0.1684917,0.1845499,0.5752646,0.003108916,0.0009499915],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":"theoretical_or_conceptual","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.980377,0.001830465,0.008235896,0.002777627,0.00007770162,0.0002276913,0.00001247575,0.00001965812,0.006441475],"genre_scores_gemma":[0.9835929,0.0001798101,0.01540845,0.0002629159,0.0003802067,0.000004138788,0.000003773272,0.00002493303,0.0001428964],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.268501,"threshold_uncertainty_score":0.9991949,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2339943063","doi":"10.1016/s1470-2045(16)00080-2","title":"Ponatinib versus imatinib for newly diagnosed chronic myeloid leukaemia: an international, randomised, open-label, phase 3 trial","year":2016,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":259,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"McGill University; Jewish General Hospital; Princess Margaret Cancer Centre","funders":"Ariad Pharmaceuticals","keywords":"Ponatinib; Medicine; Imatinib; Internal medicine; Myeloid leukemia; Imatinib mesylate; Oncology; Clinical trial; Clinical endpoint; Nilotinib","retraction":null,"screen_n_in":null,"score":{"opus":0.1491709117621627,"gpt":0.447745619994161,"spread":0.2985747082319983,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.001372379,0.0003038144,0.001052878,0.00008199015,0.0001735542,0.0000479604,0.001076991,0.0002468505,0.001046664],"category_scores_gemma":[0.001796795,0.0001694616,0.0001246898,0.0001175212,0.0002407655,0.000309152,0.0002343147,0.0002621197,0.0001616997],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.003405822,"about_ca_system_score_gemma":0.002080399,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0001090341,"about_ca_topic_score_gemma":0.0002716029,"domain_scores_codex":[0.9975819,0.0003292638,0.0006078525,0.0005504899,0.0002936587,0.0006368104],"domain_scores_gemma":[0.9948601,0.003451472,0.0003922049,0.0009277494,0.0001705409,0.0001980007],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.7218275,0.00199425,0.00003442387,0.00003246378,0.0006702495,0.0001029528,0.0002604377,0.000002309815,0.007634851,0.001765154,0.0245733,0.2411021],"study_design_scores_gemma":[0.7431617,0.01262436,0.00005772259,0.00006655265,0.0002864519,0.00005257992,0.00004404226,0.0003264584,0.001004969,0.0002840867,0.2419284,0.0001627397],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9421853,0.0003561066,0.000600168,0.02501865,0.004449434,0.008364982,0.0002988756,0.0001885534,0.01853786],"genre_scores_gemma":[0.9525493,0.002395934,0.01047381,0.004170938,0.01580963,0.007238053,0.0007140893,0.0001755021,0.00647276],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.2409394,"threshold_uncertainty_score":0.9998665,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2130008150","doi":"10.1073/pnas.0900189106","title":"Glycogen synthase kinase 3β missplicing contributes to leukemia stem cell generation","year":2009,"lang":"en","type":"article","venue":"Proceedings of the National Academy of Sciences","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":240,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Cancer Institute; National Heart, Lung, and Blood Institute; University of California, San Diego","keywords":"Biology; Progenitor cell; Cancer research; Stem cell; Wnt signaling pathway; Myeloid leukemia; Cancer stem cell; Haematopoiesis; Leukemia; Population; Immunology; Cell biology; Medicine; Signal transduction","retraction":null,"screen_n_in":null,"score":{"opus":0.04238527604128569,"gpt":0.3078284576067045,"spread":0.2654431815654188,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007502655,0.0001292286,0.0002365317,0.0002075758,0.0001818755,0.00002380974,0.0003647199,0.00009226727,0.00001283336],"category_scores_gemma":[0.0002672562,0.0000878319,0.00008641456,0.0007685092,0.0002308919,0.0002236702,0.00005893482,0.0001357512,0.000005799985],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006549984,"about_ca_system_score_gemma":0.0002088789,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00001287098,"about_ca_topic_score_gemma":7.615425e-8,"domain_scores_codex":[0.9980972,0.000005351141,0.000378183,0.0003046457,0.001009438,0.0002051776],"domain_scores_gemma":[0.9992013,0.00007051305,0.0002925454,0.00001513274,0.0003336834,0.00008682522],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.00005182674,0.00007327705,0.001743572,0.00004895637,0.00001804495,6.408357e-8,0.0001469742,0.0002034377,0.9876461,0.005081108,0.002602945,0.002383686],"study_design_scores_gemma":[0.0009082917,0.0001917704,0.02099655,0.0002013219,0.00005851506,0.00001518075,0.0001064106,0.002869943,0.972379,0.001819109,0.0003718197,0.00008204523],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9870649,0.0003434051,0.000004839555,0.007427456,0.00001986452,0.0004680584,0.00001293474,0.0000188478,0.004639714],"genre_scores_gemma":[0.9961993,0.00002098447,0.001532788,0.00150384,0.0001362085,0.00001113057,6.001075e-7,0.000004808828,0.0005903186],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.01925298,"threshold_uncertainty_score":0.3581681,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2084452268","doi":"10.1182/blood-2003-09-3032","title":"Imatinib mesylate (STI571) for treatment of children with Philadelphia chromosome-positive leukemia: results from a Children's Oncology Group phase 1 study","year":2004,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":238,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Université de Montréal","funders":"","keywords":"Medicine; Imatinib mesylate; Imatinib; Nausea; Pharmacokinetics; Internal medicine; Gastroenterology; Vomiting; Myeloid leukemia; Philadelphia chromosome; Chromosomal translocation","retraction":null,"screen_n_in":null,"score":{"opus":0.01754745499324663,"gpt":0.2983391117999296,"spread":0.280791656806683,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0001350289,0.0005818872,0.001295876,0.0001728113,0.0001452452,0.00001636485,0.0001790735,0.0002312327,0.00003731551],"category_scores_gemma":[0.00007300369,0.00042786,0.0002473291,0.0002865663,0.0001776553,0.0001085858,0.00005044226,0.0001579995,0.00002041189],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.002418214,"about_ca_system_score_gemma":0.001296766,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.003517221,"about_ca_topic_score_gemma":0.0003494878,"domain_scores_codex":[0.9971316,0.00008222337,0.0008200661,0.0009770942,0.0004238331,0.0005652003],"domain_scores_gemma":[0.9979454,0.0002412077,0.0005225489,0.0008629623,0.0001429161,0.0002849368],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"nonrandomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.09530216,0.4750116,0.1803747,0.0001917956,0.09228245,0.004246583,0.04953761,0.0007938718,0.04281254,0.0002528294,0.0005005338,0.05869333],"study_design_scores_gemma":[0.5771782,0.1031726,0.251062,0.0003223103,0.009355553,0.0006817995,0.0003839389,0.0000248519,0.05713467,0.000093384,0.00005638709,0.0005343846],"study_design_candidate":"randomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.989036,0.0005872685,0.00008191389,0.0004404008,0.00006290327,0.006528683,0.002881037,0.0001316403,0.0002501205],"genre_scores_gemma":[0.9896966,0.0001250401,0.005547055,0.00006568339,0.0003645252,0.0005542259,0.003508245,0.00009485279,0.00004380283],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.481876,"threshold_uncertainty_score":0.9998173,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W1997397403","doi":"10.1182/blood-2008-03-147744","title":"Multidrug resistance gene (MDR1) polymorphisms are associated with major molecular responses to standard-dose imatinib in chronic myeloid leukemia","year":2008,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":233,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Université de Montréal; Centre Hospitalier Universitaire Sainte-Justine","funders":"","keywords":"Imatinib; Myeloid leukemia; Genotype; Single-nucleotide polymorphism; Pharmacogenetics; Imatinib mesylate; Haplotype; Allele; Medicine; Leukemia; Internal medicine; Immunology; Oncology; Biology; Genetics; Gene","retraction":null,"screen_n_in":null,"score":{"opus":0.01370123802848771,"gpt":0.248948420350487,"spread":0.2352471823219993,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0003095047,0.0004913716,0.0008701339,0.0003352401,0.0001730503,0.00002212752,0.0002400249,0.0002093614,0.0001170918],"category_scores_gemma":[0.0006693738,0.0004354549,0.0001332134,0.0008511039,0.0001622298,0.0001109627,0.0000944455,0.0004168539,0.00008753937],"about_ca_system_candidate":true,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.006921728,"about_ca_system_score_gemma":0.003639787,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0002822603,"about_ca_topic_score_gemma":0.001253977,"domain_scores_codex":[0.9966824,0.0001907894,0.0005859634,0.0007972305,0.0008998432,0.0008437796],"domain_scores_gemma":[0.9980398,0.0001839584,0.0002718111,0.0009379059,0.0001818733,0.0003845832],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","study_design_scores_codex":[0.02018226,0.003399401,0.2521656,0.0004479951,0.002759461,0.06814837,0.004698798,0.0005214671,0.6427685,0.00008096295,0.003785842,0.001041261],"study_design_scores_gemma":[0.06663539,0.001600131,0.5387154,0.001991193,0.0005851089,0.0006936874,0.0001346765,0.00007558693,0.3874589,0.00002355137,0.001230698,0.0008557105],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9936861,0.00316505,0.00005716173,0.0005674498,0.00004928509,0.00132836,0.0002342087,0.0002086303,0.0007038036],"genre_scores_gemma":[0.9880315,0.0001305302,0.005500894,0.0004261274,0.00009382013,0.000219248,0.0001166862,0.0001308491,0.005350352],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.2865497,"threshold_uncertainty_score":0.9998097,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2412914653","doi":"10.1038/nature18288","title":"Dual targeting of p53 and c-MYC selectively eliminates leukaemic stem cells","year":2016,"lang":"en","type":"article","venue":"Nature","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":229,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Discovery Centre","funders":"Medical Research Council; Imperial Experimental Cancer Medicine Centre; Howat Foundation; Cancer Research UK; Constellation Pharmaceuticals","keywords":"Stem cell; Cancer research; Tyrosine kinase; Haematopoiesis; Imatinib mesylate; Biology; Imatinib; Bruton's tyrosine kinase; breakpoint cluster region; Myeloid leukemia; Cell biology; Signal transduction; Receptor; Genetics","retraction":null,"screen_n_in":null,"score":{"opus":0.007148326169444772,"gpt":0.2449901059690739,"spread":0.2378417797996292,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001138634,0.0001428698,0.0002548957,0.00006705482,0.00003250355,0.000003978205,0.00004658447,0.0005781399,0.00006852869],"category_scores_gemma":[0.00005718867,0.00008718829,0.00004827557,0.0001153647,0.00006075611,0.00006128854,0.00004102125,0.0005670736,0.00001891042],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003419416,"about_ca_system_score_gemma":0.0001724771,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00001287448,"about_ca_topic_score_gemma":0.000002535088,"domain_scores_codex":[0.9991248,0.0000265646,0.0001646501,0.0002543775,0.0002131342,0.0002164415],"domain_scores_gemma":[0.9993866,0.0001723191,0.00008800238,0.000151392,0.0001194648,0.00008223799],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.0002451855,0.00008769838,0.02431343,0.0001971485,0.000173754,0.00007584912,0.0004015675,4.317466e-7,0.9289166,0.0001489521,0.01412843,0.03131091],"study_design_scores_gemma":[0.004420636,0.0003493671,0.02339914,0.0003883032,0.0001386842,0.0001033687,0.0001462299,0.0000251815,0.9639847,0.00008667005,0.006807631,0.0001500467],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9939402,0.004108885,0.000009013463,0.0006919532,0.0001226926,0.0002209769,0.00002751516,0.00004330663,0.0008354476],"genre_scores_gemma":[0.9962745,0.0002000258,0.0005728015,0.0001487835,0.0001532671,0.000005669132,0.000004728264,0.00002208623,0.002618125],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.03506809,"threshold_uncertainty_score":0.4459144,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2015018636","doi":"10.1182/blood-2014-12-615757","title":"IgH-V(D)J NGS-MRD measurement pre- and early post-allotransplant defines very low- and very high-risk ALL patients","year":2015,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":224,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"BC Children's Hospital; University of British Columbia","funders":"National Institutes of Health; National Cancer Institute; National Heart, Lung, and Blood Institute; St. Baldrick's Foundation","keywords":"Medicine; Oncology; Internal medicine; Cohort","retraction":null,"screen_n_in":null,"score":{"opus":0.01667898044994222,"gpt":0.2156055388238983,"spread":0.1989265583739561,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0002498665,0.0003034523,0.0004081318,0.00009632327,0.00006304536,0.00003720094,0.00007880512,0.000140708,0.000009908802],"category_scores_gemma":[0.0001550116,0.0002471432,0.00005704815,0.00007427834,0.00007541256,0.0001430048,0.00006671798,0.0001885952,0.00003228211],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002449311,"about_ca_system_score_gemma":0.0002694188,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002207936,"about_ca_topic_score_gemma":0.0001541911,"domain_scores_codex":[0.9980645,0.00006295159,0.0003196069,0.0004563494,0.0007157613,0.0003807844],"domain_scores_gemma":[0.9988036,0.00004974369,0.000112217,0.0003518408,0.0002570087,0.0004255954],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.0009157292,0.001696607,0.989296,0.000314682,0.0009378964,0.0001733709,0.001512588,0.000001897522,0.002376667,0.00002821847,0.0003700959,0.002376265],"study_design_scores_gemma":[0.02905807,0.002216764,0.9610864,0.0003881011,0.001627676,0.00008519724,0.00003333368,0.000007859786,0.004517012,0.00005512814,0.0006541516,0.0002703208],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9957507,0.002766511,0.000004628781,0.0001278689,0.0001992654,0.0006637211,0.00008450195,0.00008543419,0.00031739],"genre_scores_gemma":[0.9983447,0.0005960881,0.0004624853,0.0001944846,0.0001168498,0.00004051665,0.0000799882,0.000044247,0.0001206789],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.0282096,"threshold_uncertainty_score":0.9999981,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2127016965","doi":"10.1182/blood.v97.11.3581","title":"Primary chromosomal rearrangements of leukemia are frequently accompanied by extensive submicroscopic deletions and may lead to altered prognosis","year":2001,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":217,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Princess Margaret Cancer Centre; Ontario Institute for Cancer Research","funders":"","keywords":"Breakpoint; Haploinsufficiency; Biology; Chromosomal translocation; breakpoint cluster region; Myeloid leukemia; Leukemia; Fluorescence in situ hybridization; Comparative genomic hybridization; Genetics; Cytogenetics; Gene rearrangement; Molecular biology; Chromosome; Cancer research; Gene; Phenotype","retraction":null,"screen_n_in":null,"score":{"opus":0.01840919972254899,"gpt":0.26336061842172,"spread":0.244951418699171,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00006897112,0.0002632745,0.0005350992,0.0001238622,0.00008352639,0.00002003095,0.0001206475,0.0001168512,0.0001099464],"category_scores_gemma":[0.00006191656,0.0002486181,0.00008072973,0.0002596122,0.00009472037,0.00008514275,0.00009684921,0.0001528876,0.00005094111],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005617577,"about_ca_system_score_gemma":0.0002633773,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0003038455,"about_ca_topic_score_gemma":0.00005336544,"domain_scores_codex":[0.9983608,0.00004210422,0.0003877749,0.0004826403,0.000316389,0.0004102874],"domain_scores_gemma":[0.9989707,0.00004074867,0.0001665794,0.0004284748,0.0001590559,0.0002344033],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.0001678758,0.00103485,0.5319323,0.0002161099,0.0004519444,0.0001605331,0.0002768465,0.000001003261,0.4569327,0.000004346618,0.007168965,0.001652525],"study_design_scores_gemma":[0.01456511,0.0007607505,0.8374406,0.0006750001,0.000750175,0.0003363797,0.0001586106,0.000009358921,0.142379,0.00001044758,0.002639898,0.0002746305],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9955279,0.001300404,0.00001216779,0.0006634938,0.00008200559,0.001219012,0.0001142051,0.00007280354,0.001008019],"genre_scores_gemma":[0.9957054,0.0002893988,0.00182919,0.0007455461,0.0001033486,0.0001463014,0.0001995882,0.00004620993,0.0009349944],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.3145537,"threshold_uncertainty_score":0.9999966,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W1947838475","doi":"10.1182/blood-2015-06-648667","title":"Pediatric chronic myeloid leukemia is a unique disease that requires a different approach","year":2015,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":216,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Child and Family Research Institute; BC Children's Hospital","funders":"National Cancer Institute; Ariad Pharmaceuticals; Pfizer; Bristol-Myers Squibb","keywords":"Medicine; Chronic myelogenous leukemia; Disease; Pediatrics; Transplantation; Myeloid leukemia; Hematopoietic stem cell transplantation; Dasatinib; Leukemia; Intensive care medicine; Immunology; Imatinib; Internal medicine","retraction":null,"screen_n_in":null,"score":{"opus":0.03734855655750234,"gpt":0.2647348544438029,"spread":0.2273862978863005,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0001491373,0.00042801,0.0005228023,0.0001868651,0.0000781404,0.00003997513,0.0002343429,0.0001708558,0.0001461804],"category_scores_gemma":[0.0001158785,0.0003317049,0.0002239317,0.0002941903,0.00008194905,0.0001296293,0.0001729611,0.000330672,0.0001856894],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.002785502,"about_ca_system_score_gemma":0.003330738,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000129257,"about_ca_topic_score_gemma":0.00001004098,"domain_scores_codex":[0.9975691,0.00008306873,0.0003322003,0.0006729222,0.0007173663,0.0006253229],"domain_scores_gemma":[0.9976447,0.00005144262,0.0001433546,0.0009899393,0.00008822912,0.001082333],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.001012833,0.006871879,0.9456397,0.002248595,0.001284668,0.001759213,0.002714853,0.00004278695,0.0009095694,0.0005669583,0.03263945,0.004309481],"study_design_scores_gemma":[0.1474091,0.004459489,0.7757365,0.0007777155,0.01477371,0.001408204,0.000758926,0.004674585,0.02437692,0.001939588,0.02060312,0.003082234],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9847261,0.008084486,0.0001218605,0.000370885,0.0001475658,0.0009865335,0.00004360704,0.0002739753,0.00524494],"genre_scores_gemma":[0.9936429,0.0008028603,0.0005804737,0.0003636584,0.001072862,0.0002441849,0.0001789206,0.0000841449,0.003029944],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1699033,"threshold_uncertainty_score":0.9999135,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2134318552","doi":"10.1158/1078-0432.ccr-07-4575","title":"Phase II, Open-Label Study Evaluating the Activity of Imatinib in Treating Life-Threatening Malignancies Known to Be Associated with Imatinib-Sensitive Tyrosine Kinases","year":2008,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":216,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Université de Montréal; Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Imatinib; Medicine; Systemic mastocytosis; Tyrosine kinase; Dermatofibrosarcoma protuberans; Imatinib mesylate; Tyrosine-kinase inhibitor; PDGFRA; Malignancy; Cancer research; Internal medicine; GiST; Oncology; Pathology; Cancer; Disease; Receptor; Stromal cell","retraction":null,"screen_n_in":null,"score":{"opus":0.5138175632808544,"gpt":0.5818905854513831,"spread":0.06807302217052869,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.007996725,0.0003232248,0.001268242,0.0002281506,0.0007206011,0.00005030341,0.0004729327,0.000142674,0.0001408374],"category_scores_gemma":[0.01756696,0.0002080112,0.0000903316,0.001744391,0.000720453,0.00020407,0.0008616828,0.001201011,0.000008475177],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001399381,"about_ca_system_score_gemma":0.003728509,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.007015721,"about_ca_topic_score_gemma":0.002763254,"domain_scores_codex":[0.9933931,0.002047641,0.001142129,0.0008681349,0.001691097,0.0008578906],"domain_scores_gemma":[0.990766,0.006345706,0.0004350927,0.0007908248,0.001294587,0.0003677572],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.05304028,0.0913493,0.5923132,0.0002895213,0.002617165,0.001854919,0.03446246,0.0003155364,0.03998404,0.00003261233,0.002587019,0.181154],"study_design_scores_gemma":[0.2063071,0.1483749,0.59541,0.005621925,0.0006744793,0.00006237694,0.009467573,0.01165086,0.02158285,0.0000272849,0.00005504267,0.0007656788],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9922057,0.0002874181,0.000007451571,0.001977816,0.00005662294,0.004601985,0.00008603269,0.00003916118,0.000737841],"genre_scores_gemma":[0.9966508,0.0001151891,0.0007931099,0.0002586977,0.0001430217,0.0009394023,0.00002487949,0.00006194146,0.001012937],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1803883,"threshold_uncertainty_score":0.9995967,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W1983717821","doi":"10.1038/sj.emboj.7601485","title":"Bcr‐Abl stabilizes β‐catenin in chronic myeloid leukemia through its tyrosine phosphorylation","year":2007,"lang":"en","type":"article","venue":"The EMBO Journal","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":215,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"McGill University","funders":"National Cancer Institute; Associazione Italiana per la Ricerca sul Cancro; Fondazione Italiana per la Ricerca sul Cancro; Ministero dell’Istruzione, dell’Università e della Ricerca","keywords":"Library science; Medicine; Humanities; Art; Computer science","retraction":null,"screen_n_in":null,"score":{"opus":0.02633029491608721,"gpt":0.2982616204707272,"spread":0.27193132555464,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.001549601,0.0003099467,0.0004449795,0.0001546712,0.0002644158,0.00005688693,0.0002693745,0.0001444574,0.00127916],"category_scores_gemma":[0.0001988973,0.0002049922,0.0001696383,0.0005256024,0.0001294936,0.0003139196,0.00007268128,0.001058811,0.0003085753],"about_ca_system_candidate":true,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.01095992,"about_ca_system_score_gemma":0.001859974,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0002090525,"about_ca_topic_score_gemma":0.0002574958,"domain_scores_codex":[0.9974131,0.0001081611,0.0007677257,0.0002980974,0.0006449775,0.0007679098],"domain_scores_gemma":[0.9987152,0.0002256296,0.0003024327,0.0003990569,0.0001614328,0.0001962817],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.01034203,0.001769795,0.07174113,0.0007757262,0.002016173,0.006165346,0.02790862,0.009308945,0.6206797,0.005799481,0.02809394,0.2153991],"study_design_scores_gemma":[0.04170216,0.002550769,0.3972456,0.001899856,0.000820599,0.01130568,0.002456516,0.005159435,0.4882127,0.005074352,0.04232284,0.001249547],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9807562,0.008919591,0.0004966477,0.001326435,0.0004846558,0.0005412065,0.000003879934,0.00006121967,0.007410193],"genre_scores_gemma":[0.9935352,0.001831064,0.0007233042,0.0003518421,0.001086008,0.00001112442,0.00001696745,0.00005786098,0.00238665],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.3255045,"threshold_uncertainty_score":0.9996338,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W1605939038","doi":"10.1038/77819","title":"SCL and LMO1 alter thymocyte differentiation: inhibition of E2A-HEB function and pre-Tα chain expression","year":2000,"lang":"en","type":"article","venue":"Nature Immunology","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":209,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Université du Québec; BioPhage Pharma (Canada); Université de Montréal; Montreal Clinical Research Institute","funders":"","keywords":"Transcription factor; Biology; CD8; Cell biology; Cellular differentiation; Thymocyte; T cell; Gene; Immunology; Genetics; Antigen; Immune system","retraction":null,"screen_n_in":null,"score":{"opus":0.004271264782695116,"gpt":0.2339531923296735,"spread":0.2296819275469784,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00006752372,0.0001520192,0.0002677639,0.0001081465,0.00006323696,0.000006994321,0.00002718955,0.0004954549,0.0005717857],"category_scores_gemma":[0.00003147691,0.0001203984,0.00003666754,0.00008917882,0.0001134687,0.0000991633,0.00003755142,0.0004358224,0.000009218043],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001307846,"about_ca_system_score_gemma":0.00004427626,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00002297906,"about_ca_topic_score_gemma":0.000006942195,"domain_scores_codex":[0.9991419,0.00006607673,0.0002134076,0.0002791498,0.0001315352,0.0001679561],"domain_scores_gemma":[0.999538,0.00005083633,0.0000882216,0.0002333791,0.00004943893,0.00004010565],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","study_design_scores_codex":[0.003526645,0.0003189266,0.01534088,0.0001862772,0.0002958139,0.00002255465,0.0006513826,0.000002334701,0.8469583,0.0003334058,0.0006595684,0.1317039],"study_design_scores_gemma":[0.01009063,0.001079749,0.8201139,0.0004769868,0.0002124586,0.0002598453,0.00004986111,0.0001657664,0.1638029,0.0007814548,0.002795701,0.0001708021],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9862638,0.0120009,0.00004219223,0.0005597553,0.0001806127,0.0003311532,0.000008135181,0.00004512653,0.0005683554],"genre_scores_gemma":[0.997034,0.00132608,0.0001713325,0.0002020126,0.0001078262,0.0000214717,0.0001346216,0.00001607865,0.0009865924],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.804773,"threshold_uncertainty_score":0.6260653,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2077014658","doi":"10.1002/pbc.21132","title":"A phase II study of imatinib mesylate in children with refractory or relapsed solid tumors: A Children's Oncology Group study","year":2007,"lang":"en","type":"article","venue":"Pediatric Blood & Cancer","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":209,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Hospital for Sick Children; Centre Hospitalier Universitaire Sainte-Justine; BC Children's Hospital","funders":"National Cancer Institute","keywords":"Medicine; Imatinib mesylate; Sarcoma; Imatinib; Osteosarcoma; Neuroblastoma; Synovial sarcoma; Refractory (planetary science); Internal medicine; Oncology; Platelet-derived growth factor receptor; Surgical oncology; Pathology; Receptor","retraction":null,"screen_n_in":null,"score":{"opus":0.01498889142586767,"gpt":0.3341036959074856,"spread":0.3191148044816179,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0007702273,0.0004951427,0.001297267,0.0006369647,0.0001217409,0.000009103348,0.0002630527,0.0001719515,0.00035059],"category_scores_gemma":[0.0001146597,0.0003575937,0.00009496637,0.001362095,0.00007477187,0.0001503584,0.0001600714,0.0007168737,0.000008458604],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0009509446,"about_ca_system_score_gemma":0.001485408,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.006661294,"about_ca_topic_score_gemma":0.00539519,"domain_scores_codex":[0.9962799,0.0001676457,0.001172706,0.0008505208,0.0007704106,0.0007588065],"domain_scores_gemma":[0.9979268,0.0001760726,0.0007154684,0.0007577621,0.0001342293,0.0002896138],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.005357285,0.07664606,0.9000333,0.000058463,0.001456657,0.0006946682,0.006689552,0.00001255769,0.0000846047,7.044029e-7,0.0001178883,0.008848256],"study_design_scores_gemma":[0.136918,0.0814051,0.7757066,0.00007534171,0.003894475,0.0002313007,0.001296863,0.000007262106,0.0001198529,0.000001638915,0.00001954019,0.0003240096],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9928217,0.001365694,0.000003348086,0.00003616375,0.0001121554,0.00531105,0.00004563229,0.0001022991,0.0002019936],"genre_scores_gemma":[0.9976386,0.0003650144,0.0002870966,0.00008894927,0.0008375762,0.0004707247,0.00004467653,0.00009427049,0.0001730409],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1315607,"threshold_uncertainty_score":0.9999534,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W1827459324","doi":"10.1002/ajh.24120","title":"Age and d<scp>PCR</scp> can predict relapse in <scp>CML</scp> patients who discontinued imatinib: The <scp>ISAV</scp> study","year":2015,"lang":"en","type":"article","venue":"American Journal of Hematology","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":209,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"McGill University; Jewish General Hospital","funders":"Regione Lombardia; Associazione Italiana per la Ricerca sul Cancro","keywords":"Imatinib; Medicine; Cancer research; Myeloid leukemia","retraction":null,"screen_n_in":null,"score":{"opus":0.01461351741340303,"gpt":0.2685303413715195,"spread":0.2539168239581165,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.001205675,0.0006382298,0.00224883,0.0005265857,0.0001508467,0.0000664887,0.0006029198,0.0001832011,0.000006320735],"category_scores_gemma":[0.006998259,0.0004362768,0.0002435974,0.0007932304,0.001107184,0.0002558519,0.0002974406,0.001271556,0.00003040868],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007483898,"about_ca_system_score_gemma":0.0008717009,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0006455681,"about_ca_topic_score_gemma":0.0004717082,"domain_scores_codex":[0.9946041,0.0009122574,0.001720644,0.000630677,0.001028043,0.001104261],"domain_scores_gemma":[0.9930577,0.002922195,0.001939728,0.0008378869,0.0003910282,0.0008514822],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.00005075192,0.001581581,0.9386661,0.00006202963,0.0007830189,0.003363203,0.02767105,0.00002013173,0.00005826067,0.00007288049,0.02505843,0.002612549],"study_design_scores_gemma":[0.03155092,0.01393272,0.8249524,0.0007293915,0.001219516,0.00721972,0.1073049,0.0002236481,0.0005443212,0.0005222928,0.01168429,0.0001158028],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9940937,0.001430367,0.00003008337,0.0004790456,0.0004938598,0.001231245,0.00003380664,0.00004776534,0.002160194],"genre_scores_gemma":[0.9971771,0.0002204266,0.000564728,0.0005915304,0.000220635,0.00006633651,0.00002732168,0.0001087668,0.001023195],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1137137,"threshold_uncertainty_score":0.9998089,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W1998936478","doi":"10.1038/leu.2008.221","title":"Efficacy and safety of dasatinib in imatinib-resistant or -intolerant patients with chronic myeloid leukemia in blast phase","year":2008,"lang":"en","type":"article","venue":"Leukemia","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":201,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"McGill University","funders":"National Cancer Institute","keywords":"Dasatinib; Medicine; Internal medicine; Chronic myelogenous leukemia; Imatinib; Neutropenia; Tolerability; Gastroenterology; Imatinib mesylate; Myeloid leukemia; Oncology; Nilotinib; Immunology; Leukemia; Adverse effect; Chemotherapy","retraction":null,"screen_n_in":null,"score":{"opus":0.01500029936148646,"gpt":0.2662409921901603,"spread":0.2512406928286739,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0002148243,0.0004891697,0.001064996,0.0003886489,0.00008809961,0.00001063413,0.0001815888,0.0002141308,0.0002388504],"category_scores_gemma":[0.000200892,0.0003582521,0.00007489072,0.0008076431,0.0003555468,0.0001797789,0.0001013513,0.0005388439,0.00002200371],"about_ca_system_candidate":true,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.01241015,"about_ca_system_score_gemma":0.005093864,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001535856,"about_ca_topic_score_gemma":0.001423404,"domain_scores_codex":[0.996794,0.00009828153,0.001093309,0.0007016123,0.0006306939,0.0006821089],"domain_scores_gemma":[0.998325,0.0003069254,0.0003356085,0.0006721066,0.000105112,0.0002552485],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.1202575,0.005019209,0.7522866,0.002865326,0.000795615,0.005308829,0.01335512,0.002912684,0.01768565,0.000141764,0.001217297,0.0781544],"study_design_scores_gemma":[0.1495878,0.003846235,0.8368438,0.001881494,0.0001140824,0.0001507294,0.00011232,0.002711413,0.003328234,0.000006775683,0.0009521703,0.0004649301],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9965484,0.0004176753,0.00002640561,0.00005235849,0.00005498561,0.001672639,0.00006048664,0.00005657603,0.001110538],"genre_scores_gemma":[0.9974586,0.0003298521,0.001358789,0.0001135329,0.0000663993,0.00008163855,0.0001647376,0.00007410962,0.0003522932],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.08455728,"threshold_uncertainty_score":0.9998869,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W1999328539","doi":"10.1182/blood-2013-07-516807","title":"The core autophagy protein ATG4B is a potential biomarker and therapeutic target in CML stem/progenitor cells","year":2014,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":199,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false},"ca_institutions":"Simon Fraser University; University of British Columbia; BC Cancer Agency","funders":"Canadian Institutes of Health Research","keywords":"Progenitor cell; Autophagy; Stem cell; Gene knockdown; Cancer research; Progenitor; Biology; Cell biology; Cell culture; Apoptosis; Genetics","retraction":null,"screen_n_in":null,"score":{"opus":0.01506847254216259,"gpt":0.2448031406450065,"spread":0.2297346681028439,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002370666,0.0001937384,0.0002479213,0.00005550583,0.0001050095,0.00003177827,0.000109593,0.000117058,0.00008263613],"category_scores_gemma":[0.00001549025,0.0001254931,0.00007122844,0.0001314348,0.00009370819,0.00002617895,0.0000592981,0.0001521613,0.00006464797],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00009965803,"about_ca_system_score_gemma":0.0001573683,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00008989365,"about_ca_topic_score_gemma":0.00001579412,"domain_scores_codex":[0.9987597,0.0000765052,0.0002467368,0.0003178003,0.0002520735,0.000347122],"domain_scores_gemma":[0.9993055,0.00005863972,0.00007792533,0.0004101741,0.00003573297,0.0001120474],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.0009553358,0.002435968,0.05017759,0.0004423738,0.001529609,0.0004931198,0.001525844,0.000002038305,0.8495797,0.0003295314,0.001260142,0.09126873],"study_design_scores_gemma":[0.04799626,0.001509622,0.1216924,0.0003848991,0.0009737751,0.0004915927,0.0002654541,0.006439146,0.7784631,0.001107418,0.04000653,0.000669782],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9948634,0.002923098,0.00001940238,0.0005570615,0.0001188845,0.001091389,0.00001023262,0.00004710098,0.0003694525],"genre_scores_gemma":[0.996482,0.00004323289,0.0004244681,0.0002863016,0.0001403244,0.0001271767,0.000006260446,0.00003455281,0.002455674],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.09059895,"threshold_uncertainty_score":0.5117459,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2054103222","doi":"10.1016/j.stem.2012.12.011","title":"A Pan-BCL2 Inhibitor Renders Bone-Marrow-Resident Human Leukemia Stem Cells Sensitive to Tyrosine Kinase Inhibition","year":2013,"lang":"en","type":"article","venue":"Cell stem cell","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":195,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false},"ca_institutions":"Princess Margaret Cancer Centre; Canada's Michael Smith Genome Sciences Centre; Ontario Institute for Cancer Research; BC Cancer Agency","funders":"National Institute of Allergy and Infectious Diseases; National Institute of General Medical Sciences; Ontario Ministry of Research and Innovation; University of California, San Diego; Canadian Institutes of Health Research; Ontario Genomics Institute; China Scholarship Council; Genome Canada; National Institutes of Health; Ontario Genomics; National Cancer Institute; Government of Canada; California Institute for Regenerative Medicine","keywords":"Biology; Stem cell; Tyrosine-kinase inhibitor; Leukemia; Bone marrow; Cancer research; Tyrosine kinase; Immunology; Cell biology; Signal transduction; Cancer; Genetics","retraction":null,"screen_n_in":null,"score":{"opus":0.01464464361081714,"gpt":0.234219884548629,"spread":0.2195752409378119,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0002787916,0.0007490744,0.000894717,0.000365459,0.0002484052,0.0001347416,0.0001546747,0.000384287,0.0005406858],"category_scores_gemma":[0.000006393363,0.0007079493,0.0003240454,0.0004881859,0.000125239,0.0002744535,0.0002369315,0.0005425306,0.005066534],"about_ca_system_candidate":true,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.005617672,"about_ca_system_score_gemma":0.0005874321,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001704669,"about_ca_topic_score_gemma":0.0001078222,"domain_scores_codex":[0.9957275,0.0001939132,0.0009579491,0.001197817,0.0008622476,0.001060571],"domain_scores_gemma":[0.9971569,0.0001460486,0.0003716922,0.001100376,0.0003330682,0.0008919319],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.000160373,0.0003857533,0.0003550972,0.0005568932,0.00006259366,0.0008477203,0.002361986,0.00007964431,0.9365446,0.0000130968,0.0562053,0.002426925],"study_design_scores_gemma":[0.007059366,0.0009365801,0.001212761,0.0005547785,0.0002785557,0.00005887731,0.002994746,0.0001807829,0.9820793,0.00001333143,0.0039557,0.000675275],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9824848,0.00048048,0.0001025959,0.0003611584,0.0005137223,0.003043008,0.00005023519,0.0002926738,0.01267136],"genre_scores_gemma":[0.9498389,0.00005710033,0.0003544803,0.0008738614,0.0004742734,0.0002410708,0.0001473149,0.000165603,0.04784735],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.0522496,"threshold_uncertainty_score":0.9995372,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W3194203975","doi":"10.1182/blood.2021012082","title":"Ponatinib dose-ranging study in chronic-phase chronic myeloid leukemia: a randomized, open-label phase 2 clinical trial","year":2021,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":193,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Princess Margaret Cancer Centre","funders":"Takeda Oncology; National Cancer Institute; National Institute for Health and Care Research","keywords":"Ponatinib; Medicine; Internal medicine; Clinical endpoint; Adverse effect; Myeloid leukemia; Cohort; Confidence interval; Oncology; Nilotinib; Clinical trial; Imatinib","retraction":null,"screen_n_in":null,"score":{"opus":0.08930478020376911,"gpt":0.4306504869785546,"spread":0.3413457067747855,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.003822922,0.000673794,0.003029006,0.0002958809,0.0001933902,0.0001704068,0.0006083202,0.0004147318,0.001098157],"category_scores_gemma":[0.002465391,0.0005961304,0.0004942097,0.0009388786,0.0002437796,0.0003027122,0.0006583408,0.001302691,0.0002260914],"about_ca_system_candidate":true,"about_ca_system_consensus":true,"about_ca_system_score_codex":0.004784893,"about_ca_system_score_gemma":0.01526273,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0004117774,"about_ca_topic_score_gemma":0.0007040055,"domain_scores_codex":[0.9926581,0.001369658,0.002503987,0.001542968,0.0008590441,0.001066291],"domain_scores_gemma":[0.9957597,0.001479406,0.0005168704,0.0015439,0.0002040813,0.00049599],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.7782721,0.1210563,0.0008118137,0.0002831655,0.004162675,0.01800925,0.001129007,0.00001967023,0.004435549,0.0001641211,0.0007772642,0.07087912],"study_design_scores_gemma":[0.977348,0.01212729,0.0001435917,0.0004686805,0.002687031,0.000356309,0.0002993701,0.001973121,0.002153189,0.0000424514,0.001889998,0.0005109959],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9783043,0.00652893,0.00004331041,0.000374358,0.0008433384,0.01017622,0.00004474366,0.0001545343,0.003530272],"genre_scores_gemma":[0.9908096,0.000917343,0.001147859,0.0003532302,0.00224001,0.001498466,0.00031305,0.0001420538,0.002578458],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1990758,"threshold_uncertainty_score":0.999815,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2157501125","doi":"10.1182/blood-2011-10-385658","title":"Rac2-MRC-cIII–generated ROS cause genomic instability in chronic myeloid leukemia stem cells and primitive progenitors","year":2012,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":187,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"BC Cancer Agency","funders":"National Institute of Diabetes and Digestive and Kidney Diseases; National Heart, Lung, and Blood Institute; Medical Research Council; Imperial Experimental Cancer Medicine Centre; University of Pennsylvania; China Scholarship Council; Cancer Institute, University of Pittsburgh; Cancer Research UK; Peking University; National Institutes of Health; Warszawski Uniwersytet Medyczny; National Cancer Institute; Uniwersytet Warszawski; Cancer Research Institute; Temple University","keywords":"Genome instability; Myeloid leukemia; Biology; Cancer research; Stem cell; Progenitor cell; Mitochondrial ROS; Haematopoiesis; Mitochondrion; Molecular biology; DNA damage; Cell biology; Genetics","retraction":null,"screen_n_in":null,"score":{"opus":0.020180924643032,"gpt":0.2512487543760032,"spread":0.2310678297329712,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0003675204,0.0004103158,0.0005878372,0.0001642712,0.00009351708,0.00002710431,0.0001155776,0.0002684256,0.00008983522],"category_scores_gemma":[0.00003302214,0.000370618,0.00009462061,0.0003244573,0.0001556266,0.0002301767,0.0001428789,0.0004219689,0.0001187009],"about_ca_system_candidate":true,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.005473753,"about_ca_system_score_gemma":0.002059696,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0003887663,"about_ca_topic_score_gemma":0.0002118417,"domain_scores_codex":[0.9975671,0.0001590135,0.0005372715,0.0005914255,0.0002968929,0.0008482998],"domain_scores_gemma":[0.9986492,0.00009501921,0.0001556969,0.000596896,0.0000777899,0.0004253769],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.0002604772,0.00152147,0.5374551,0.0004883655,0.0006022286,0.0001925635,0.002087902,0.00002883009,0.4515705,0.00003374523,0.00008243782,0.005676415],"study_design_scores_gemma":[0.01821449,0.0004644044,0.3604398,0.0001719473,0.0006695533,0.0002386659,0.0002294634,0.0001774601,0.6177486,0.00000384572,0.001208229,0.0004335351],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9923305,0.00498409,0.000003262256,0.00003008668,0.0002217311,0.001779487,0.00004946236,0.0001191435,0.0004822443],"genre_scores_gemma":[0.9979683,0.0003573873,0.0003315253,0.00007069096,0.0004789235,0.0001853628,0.00005205095,0.00007416528,0.0004816606],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1770153,"threshold_uncertainty_score":0.9998746,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2162340188","doi":"10.1158/1078-0432.ccr-09-0145","title":"Clinical Relevance of a Pharmacogenetic Approach Using Multiple Candidate Genes to Predict Response and Resistance to Imatinib Therapy in Chronic Myeloid Leukemia","year":2009,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":186,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"University of Toronto; University Health Network","funders":"","keywords":"Myeloid leukemia; Imatinib; Pharmacogenetics; Medicine; Clinical significance; Oncology; Gene; Bioinformatics; Immunology; Internal medicine; Biology; Genetics; Genotype","retraction":null,"screen_n_in":null,"score":{"opus":0.1807922541795707,"gpt":0.5079772695143526,"spread":0.3271850153347819,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.009065558,0.0003159706,0.00111041,0.0003963319,0.0001245325,0.00003031855,0.00044303,0.0002864939,0.00006634821],"category_scores_gemma":[0.004326935,0.0002744836,0.0001841553,0.001299222,0.0005025854,0.00008632083,0.0002248429,0.001170138,0.0000149097],"about_ca_system_candidate":true,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.003676291,"about_ca_system_score_gemma":0.006386054,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0006046504,"about_ca_topic_score_gemma":0.0005150544,"domain_scores_codex":[0.9929649,0.001985891,0.001740841,0.001265828,0.001051118,0.0009914507],"domain_scores_gemma":[0.9941334,0.003365983,0.0001951628,0.0009960899,0.0004261435,0.000883203],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"observational","study_design_scores_codex":[0.09899376,0.001124662,0.3228037,0.0004196903,0.0002665048,0.0002369558,0.0007445011,0.001345575,0.09314897,0.00000937251,0.003584772,0.4773216],"study_design_scores_gemma":[0.03337395,0.008379229,0.9013364,0.002011678,0.00009311992,0.00002769711,0.0001254088,0.01597733,0.01469128,0.00009825843,0.02331308,0.0005725949],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.982362,0.01263537,0.0001651431,0.001637002,0.0001338041,0.002800034,0.00006482929,0.00003769185,0.000164137],"genre_scores_gemma":[0.9729668,0.01513389,0.009576217,0.0008468552,0.0005697248,0.0002583863,0.000009882847,0.00005785718,0.0005804034],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.5785327,"threshold_uncertainty_score":0.9999707,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2067382049","doi":"10.1038/onc.2010.67","title":"Imatinib resistance associated with BCR-ABL upregulation is dependent on HIF-1α-induced metabolic reprograming","year":2010,"lang":"en","type":"article","venue":"Oncogene","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":176,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"BC Cancer Agency","funders":"National Cancer Institute","keywords":"Biology; Imatinib mesylate; Cancer research; Transketolase; Imatinib; Myeloid leukemia; Biochemistry; Enzyme","retraction":null,"screen_n_in":null,"score":{"opus":0.0199216976062795,"gpt":0.2846204596258328,"spread":0.2646987620195533,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003580896,0.0002876189,0.0004594183,0.0001062653,0.0001580766,0.00003788595,0.0001213318,0.0002127128,0.0003376446],"category_scores_gemma":[0.0002900391,0.0002310452,0.0001052457,0.0003833291,0.00004764126,0.00009341777,0.00003358298,0.0003898517,0.0001184819],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000590121,"about_ca_system_score_gemma":0.0003570383,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0001098395,"about_ca_topic_score_gemma":0.0007735496,"domain_scores_codex":[0.9978747,0.00005897785,0.0003557682,0.0006014289,0.0006881807,0.000420898],"domain_scores_gemma":[0.9983422,0.0001006145,0.0002859581,0.0008991067,0.000176257,0.0001958867],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.001356719,0.001740951,0.03600774,0.00009595972,0.001587617,0.0004566958,0.001475866,0.00001892011,0.8012947,0.0008917644,0.001153711,0.1539194],"study_design_scores_gemma":[0.01338139,0.0007443668,0.1807886,0.0005041314,0.0009047029,0.00009381738,0.00009387247,0.0004639649,0.7912003,0.0001828123,0.01106781,0.0005741396],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.988201,0.0002241628,0.00003366099,0.0006206114,0.0002227305,0.0007167023,0.00002183482,0.000183952,0.009775395],"genre_scores_gemma":[0.9880343,0.00002078139,0.004173029,0.0003199269,0.0002279221,0.00008861599,0.0001441662,0.0000698867,0.00692135],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1533452,"threshold_uncertainty_score":0.942175,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2052054991","doi":"10.1182/blood-2012-02-410688","title":"A randomized trial of dasatinib 100 mg versus imatinib 400 mg in newly diagnosed chronic-phase chronic myeloid leukemia","year":2012,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":176,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false},"ca_institutions":"University of Toronto","funders":"Canadian Cancer Society Research Institute; Ariad Pharmaceuticals; National Cancer Institute; National Institutes of Health; Pfizer; Oregon Health and Science University; Bristol-Myers Squibb","keywords":"Dasatinib; Medicine; Nilotinib; Imatinib; Internal medicine; Myeloid leukemia; Imatinib mesylate; Gastroenterology; Randomized controlled trial; Tyrosine-kinase inhibitor; Immunology; Cancer","retraction":null,"screen_n_in":null,"score":{"opus":0.02894547002878551,"gpt":0.3226977424825182,"spread":0.2937522724537327,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.001436961,0.0006087847,0.002236428,0.0003614645,0.00008010469,0.00002358639,0.0003122594,0.0003935044,0.001246835],"category_scores_gemma":[0.001703846,0.0005222813,0.0006187774,0.0005724076,0.0003250446,0.000287436,0.0001437536,0.000587173,0.0002135838],"about_ca_system_candidate":true,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.003880346,"about_ca_system_score_gemma":0.004057211,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0009030135,"about_ca_topic_score_gemma":0.0002174415,"domain_scores_codex":[0.9954041,0.0004541902,0.001559097,0.0006043655,0.0007913418,0.001186875],"domain_scores_gemma":[0.9959253,0.001741481,0.0006449625,0.001127976,0.0000971738,0.0004630778],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9590154,0.007804067,0.0006986758,0.0005848236,0.001621331,0.000238727,0.001765139,0.00002921955,0.0114558,0.0002918354,0.0006282524,0.01586678],"study_design_scores_gemma":[0.9748926,0.003504396,0.0004699435,0.0004782845,0.001789529,0.0000541681,0.00009312493,0.0005897876,0.01606111,0.00002186749,0.001635789,0.0004093538],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9807906,0.006998977,0.00003035962,0.0001548778,0.001051294,0.00490052,0.00005332928,0.0001397576,0.005880256],"genre_scores_gemma":[0.9939719,0.0009143878,0.001183785,0.0000615697,0.002115814,0.0009377434,0.0002541439,0.0001111439,0.000449514],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.01587729,"threshold_uncertainty_score":0.9999436,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4366822278","doi":"10.1038/s41408-023-00823-9","title":"Management of chronic myeloid leukemia in 2023 – common ground and common sense","year":2023,"lang":"en","type":"review","venue":"Blood Cancer Journal","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":172,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Bosutinib; Dasatinib; Nilotinib; Ponatinib; Medicine; Imatinib; Oncology; Imatinib mesylate; Internal medicine; Myeloid leukemia; Intensive care medicine","retraction":null,"screen_n_in":null,"score":{"opus":0.04700418793668781,"gpt":0.3555606265684206,"spread":0.3085564386317328,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0005946244,0.0006285968,0.002934435,0.000561639,0.0001011462,0.00004978041,0.0002358786,0.0003660785,0.0002021045],"category_scores_gemma":[0.00001008449,0.0005152506,0.0004624184,0.0007371962,0.0001277735,0.00008481888,0.0002609763,0.001472123,0.0000463412],"about_ca_system_candidate":true,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.009049076,"about_ca_system_score_gemma":0.002934189,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001547206,"about_ca_topic_score_gemma":0.001101683,"domain_scores_codex":[0.9965308,0.0002156597,0.001473409,0.0005083174,0.0006344736,0.0006372989],"domain_scores_gemma":[0.9979796,0.0001587137,0.0009320317,0.0005801506,0.00005467773,0.000294789],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.00005483382,0.0001631302,0.0003258849,0.05667026,0.003736373,0.008883324,0.00006771093,0.00001332383,0.000001639298,0.00003486424,0.0008256052,0.9292231],"study_design_scores_gemma":[0.01431398,0.0007614488,0.00295649,0.2564664,0.0177066,0.01208324,0.0001432029,0.00005377881,0.00001062533,0.0001262948,0.6945491,0.0008289149],"study_design_candidate":"design_other","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.009163806,0.9879308,7.121739e-7,0.00004899655,0.0005313035,0.00118647,0.00009092603,0.00003590191,0.001011121],"genre_scores_gemma":[0.0003936514,0.9957544,0.00008416923,0.00002741769,0.0006702226,0.0001663176,0.00008002282,0.000145618,0.002678168],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.9283941,"threshold_uncertainty_score":0.9997299,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2128816533","doi":"10.3324/haematol.2009.017178","title":"Bone marrow mesenchymal stromal cells non-selectively protect chronic myeloid leukemia cells from imatinib-induced apoptosis via the CXCR4/CXCL12 axis","year":2010,"lang":"en","type":"article","venue":"Haematologica","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":169,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Institute of Cancer Research","funders":"Medical Research Council; Cancer Research UK","keywords":"Mesenchymal stem cell; Myeloid leukemia; Cancer research; Imatinib; Stromal cell; Bone marrow; Progenitor cell; Leukemia; Imatinib mesylate; Stem cell; Immunology; Biology; Cell biology","retraction":null,"screen_n_in":null,"score":{"opus":0.01425844564813957,"gpt":0.2467644451454297,"spread":0.2325059994972901,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0005348166,0.0009398994,0.00153901,0.0001887664,0.0005772763,0.0001147186,0.0007544493,0.0008278012,0.002587195],"category_scores_gemma":[0.0002093457,0.0006188556,0.0005315741,0.0005487046,0.0004321457,0.0002166288,0.0003422409,0.002113593,0.002024055],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001787748,"about_ca_system_score_gemma":0.001522386,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00153961,"about_ca_topic_score_gemma":0.0004283439,"domain_scores_codex":[0.9949725,0.0002673748,0.001009967,0.001376732,0.0009524041,0.001421066],"domain_scores_gemma":[0.9963851,0.0005906736,0.0006140639,0.001765297,0.0001665483,0.0004783396],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.0004239082,0.0003251096,0.001276572,0.0001629332,0.0004223399,0.0003405571,0.0005130567,0.000006622472,0.9863181,0.00004770686,0.002650416,0.007512689],"study_design_scores_gemma":[0.005310959,0.001372249,0.01487336,0.0001788761,0.0004532772,0.0006589424,0.0001280377,0.00216491,0.9722584,0.0002497108,0.001668449,0.0006827972],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9899568,0.0002617319,0.0003084104,0.0009106673,0.0008836378,0.003667579,0.00007555393,0.000388889,0.003546716],"genre_scores_gemma":[0.989628,0.00007127603,0.007484875,0.0003168872,0.0006240855,0.0008882241,0.0001013681,0.0001256144,0.0007596915],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.01405966,"threshold_uncertainty_score":0.9996263,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W1971880154","doi":"10.1182/blood-2010-06-291641","title":"Establishment of the first World Health Organization International Genetic Reference Panel for quantitation of BCR-ABL mRNA","year":2010,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":158,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"University Health Network","funders":"","keywords":"Philadelphia chromosome; Chronic myelogenous leukemia; ABL; Medicine; Biology; Leukemia; Immunology; Internal medicine; Genetics; Chromosomal translocation; Gene; Tyrosine kinase","retraction":null,"screen_n_in":null,"score":{"opus":0.02817571188612836,"gpt":0.2829879936704769,"spread":0.2548122817843486,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00009970389,0.00006950487,0.0001416956,0.00006798468,0.00004074313,0.000005824419,0.0001197344,0.00003506699,0.0001136889],"category_scores_gemma":[0.000254809,0.00005147797,0.00003256537,0.0002126768,0.00003497668,0.00003566694,0.00003203494,0.00007755531,0.000003050719],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00009574693,"about_ca_system_score_gemma":0.0003661035,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0002237603,"about_ca_topic_score_gemma":0.0008134355,"domain_scores_codex":[0.9992681,0.00001071907,0.0002780636,0.0001301833,0.0002166909,0.0000963108],"domain_scores_gemma":[0.9991509,0.00006861814,0.0002478984,0.0002497789,0.0002478941,0.00003489802],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.0001256663,0.002595599,0.9184386,0.0008031566,0.000407142,0.000001881999,0.001586837,0.00008605814,0.05855437,0.005884725,0.002159631,0.009356349],"study_design_scores_gemma":[0.006711137,0.0003137383,0.8950218,0.0002418238,0.0001994133,0.00002131849,0.00007543534,0.0003508326,0.09168604,0.000195957,0.005099687,0.00008284522],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9967553,0.00007732601,0.0002126515,0.001572669,0.0003019127,0.0005559372,0.00003969959,0.0000134026,0.0004711203],"genre_scores_gemma":[0.9928087,0.00004401531,0.00652069,0.0001199755,0.00006650055,0.00001723792,0.00008841111,0.00001349837,0.000320976],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.03313167,"threshold_uncertainty_score":0.2099211,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2151724015","doi":"10.1016/j.cell.2011.08.046","title":"Targeting the SH2-Kinase Interface in Bcr-Abl Inhibits Leukemogenesis","year":2011,"lang":"en","type":"article","venue":"Cell","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":152,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false},"ca_institutions":"University of Toronto; Lunenfeld-Tanenbaum Research Institute; Mount Sinai Hospital","funders":"Basic Energy Sciences; Canadian Institutes of Health Research; National Cancer Institute; National Institutes of Health; Austrian Science Fund; National Center for Research Resources; National Institute of General Medical Sciences; Österreichischen Akademie der Wissenschaften; University of Chicago; European Molecular Biology Organization; U.S. Department of Energy","keywords":"Biology; Interface (matter); Cell biology; ABL; Cancer research; Kinase; Tyrosine kinase; Signal transduction; Genetics; Computational biology; Biochemistry","retraction":null,"screen_n_in":null,"score":{"opus":0.02668374775510418,"gpt":0.2497793741398237,"spread":0.2230956263847196,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002253738,0.0001762865,0.0002182985,0.0000727511,0.00005495772,0.000008721147,0.0001479188,0.0000862751,0.0007812458],"category_scores_gemma":[0.00006820213,0.0001207454,0.00006804967,0.0002061422,0.00006438494,0.00005549632,0.0001054196,0.0002209369,0.0005833565],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006199139,"about_ca_system_score_gemma":0.0002063912,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0005967612,"about_ca_topic_score_gemma":0.00004407002,"domain_scores_codex":[0.9988899,0.00005777385,0.0002647097,0.0002871466,0.0001602681,0.0003401552],"domain_scores_gemma":[0.9993289,0.00006295391,0.00007317259,0.0004034148,0.00003471579,0.00009686431],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.00151219,0.003193299,0.2495826,0.001027073,0.0003356154,0.002100064,0.04050367,0.0002624761,0.6280935,0.0001795474,0.04008104,0.03312895],"study_design_scores_gemma":[0.004848591,0.0002458283,0.01656028,0.0001984643,0.000116089,0.00004508209,0.001253162,0.0009382892,0.9653006,0.00006890079,0.01016812,0.0002566151],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9686784,0.002126992,0.00007448506,0.0001704219,0.000163107,0.000400313,0.000002668517,0.00005286105,0.02833078],"genre_scores_gemma":[0.9942175,0.0001152692,0.0008040576,0.0002612866,0.00008775017,0.00003082633,0.000009008471,0.00003474844,0.004439622],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.3372071,"threshold_uncertainty_score":0.8554093,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2981763967","doi":"10.1080/10428194.2019.1675879","title":"Dasatinib discontinuation in patients with chronic-phase chronic myeloid leukemia and stable deep molecular response: the DASFREE study","year":2019,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":150,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre","funders":"Bristol-Myers Squibb","keywords":"Dasatinib; Discontinuation; Medicine; Myeloid leukemia; Internal medicine; Imatinib; Tyrosine-kinase inhibitor; Adverse effect; Tyrosine kinase; Oncology; Gastroenterology; Cancer; Receptor","retraction":null,"screen_n_in":null,"score":{"opus":0.005489341495418336,"gpt":0.237756561886154,"spread":0.2322672203907357,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.001239653,0.001364847,0.0016398,0.0005677043,0.0004887492,0.0003117461,0.0006338631,0.0005489395,0.0002009546],"category_scores_gemma":[0.0002329768,0.00100146,0.0002097902,0.001187236,0.0005746058,0.0007897553,0.0005378468,0.0004808874,0.0001228701],"about_ca_system_candidate":true,"about_ca_system_consensus":true,"about_ca_system_score_codex":0.04769249,"about_ca_system_score_gemma":0.01162797,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00296978,"about_ca_topic_score_gemma":0.001302786,"domain_scores_codex":[0.9924703,0.0006878093,0.001413713,0.002131657,0.001589482,0.001707061],"domain_scores_gemma":[0.9954694,0.0006597249,0.0006488294,0.002334487,0.0002657352,0.000621806],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.02816241,0.003094495,0.6569465,0.0007544224,0.001706516,0.001338179,0.006986037,0.001246214,0.008746474,0.0004095305,0.0005692219,0.29004],"study_design_scores_gemma":[0.1571587,0.008724243,0.8130581,0.0006995277,0.000684537,0.0002709673,0.001284921,0.01090031,0.002171424,0.00005100688,0.003805371,0.001190952],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9886814,0.003611557,0.00007097985,0.0002041836,0.0002723031,0.00592502,0.00006438288,0.0002204425,0.0009497759],"genre_scores_gemma":[0.9959876,0.0002713385,0.0002725173,0.0004686314,0.0002194887,0.0005552887,0.0003368316,0.0002630394,0.001625245],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.288849,"threshold_uncertainty_score":0.9999102,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2075548587","doi":"10.1182/blood.v97.3.720","title":"Primitive quiescent leukemic cells from patients with chronic myeloid leukemia spontaneously initiate factor-independent growth in vitro in association with up-regulation of expression of interleukin-3","year":2001,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":150,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false},"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"BC Cancer Agency","keywords":"Biology; Myeloid leukemia; CD38; Interleukin 3; Progenitor cell; CD34; Leukemia; Cancer research; Population; Myeloid; Molecular biology; Growth factor; ABL; Immunology; Stem cell; Cell biology; T cell; Interleukin 21; Signal transduction; Immune system; Tyrosine kinase; Medicine; Receptor; Genetics","retraction":null,"screen_n_in":null,"score":{"opus":0.006904935077660119,"gpt":0.2076230744175077,"spread":0.2007181393398476,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0001414366,0.0003551275,0.0007408382,0.0003544258,0.00002466763,0.00001021862,0.0001427297,0.0002458018,0.00009360717],"category_scores_gemma":[0.00006111819,0.0002858075,0.00007952153,0.0003879508,0.00005906272,0.0002232634,0.00006647455,0.0003755505,0.000007067269],"about_ca_system_candidate":true,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.009409653,"about_ca_system_score_gemma":0.00115155,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.003885922,"about_ca_topic_score_gemma":0.001468875,"domain_scores_codex":[0.9972375,0.0001419704,0.0007563778,0.0005106286,0.0009215679,0.0004319543],"domain_scores_gemma":[0.9983366,0.0001876513,0.0007781984,0.0003494164,0.0002432073,0.0001049502],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.003675319,0.001087687,0.6501434,0.0001155273,0.0001676212,0.0001356671,0.00155046,0.0000963778,0.3422419,0.000001696228,0.000004614049,0.000779718],"study_design_scores_gemma":[0.02065986,0.000686196,0.4860786,0.0009987284,0.0001303682,0.00001299825,0.00008894511,0.00005332558,0.4911367,0.000009569485,0.000002854798,0.000141811],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9982541,0.0001061536,0.0000489549,0.00001077337,0.00007855275,0.001150671,0.0001140864,0.00003076319,0.0002059108],"genre_scores_gemma":[0.9988772,0.00009888486,0.0003448944,0.00001892354,0.00004931047,0.00004618175,0.0004291591,0.00005441918,0.00008103267],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1640648,"threshold_uncertainty_score":0.9999594,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2066023838","doi":"10.1016/j.exphem.2003.10.010","title":"SCL: From the origin of hematopoiesis to stem cells and leukemia","year":2004,"lang":"en","type":"review","venue":"Experimental Hematology","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":149,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false},"ca_institutions":"Université de Montréal; Institute for Research in Immunology and Cancer","funders":"National Cancer Institute; Canadian Institutes of Health Research","keywords":"Haematopoiesis; Transcription factor; Biology; Stem cell; Regulator; Hematopoietic stem cell; Leukemia; Cell biology; Transcription (linguistics); Genetics; Gene; Lineage (genetic); Computational biology; Cancer research","retraction":null,"screen_n_in":null,"score":{"opus":0.04608980461120263,"gpt":0.3493217444556989,"spread":0.3032319398444963,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0000903793,0.0006001104,0.002929091,0.000122817,0.00007356385,0.00001303671,0.000296258,0.0004300282,0.0003732667],"category_scores_gemma":[0.00001138984,0.0003859703,0.0003825494,0.0002309649,0.0002504073,0.00003243343,0.0003067132,0.0003194669,0.00035144],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.002327751,"about_ca_system_score_gemma":0.001249496,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0005028759,"about_ca_topic_score_gemma":0.00001180055,"domain_scores_codex":[0.9976477,0.0001249745,0.0008501807,0.0006912106,0.0002854247,0.0004004917],"domain_scores_gemma":[0.9981604,0.0003526415,0.000346725,0.0008780556,0.00002664515,0.0002355243],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0009974013,0.0036237,0.0005253495,0.1285663,0.01254593,0.004854668,0.0167191,0.000003575484,0.001541488,0.08698813,0.0397061,0.7039283],"study_design_scores_gemma":[0.003209329,0.0005056697,0.000004794249,0.03101847,0.001519463,0.002569407,0.00102647,0.000001430194,0.07388378,0.00004395727,0.8856441,0.0005731451],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.003212026,0.9938974,0.000006631064,0.00006222096,0.0003374718,0.001821551,0.0001174163,0.00005318,0.0004920887],"genre_scores_gemma":[0.004303883,0.9925686,0.001393466,0.0001996869,0.0001412443,0.0004397892,0.000112427,0.0001386686,0.0007022957],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.845938,"threshold_uncertainty_score":0.9998592,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2950655888","doi":"10.1038/s41375-019-0512-y","title":"Laying the foundation for genomically-based risk assessment in chronic myeloid leukemia","year":2019,"lang":"en","type":"review","venue":"Leukemia","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":149,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"National Cancer Institute; National Institute for Health and Care Research; Howard Hughes Medical Institute","keywords":"Myeloid leukemia; Disease; Medicine; Drug resistance; Cancer; Bioinformatics; Intensive care medicine; Oncology; Internal medicine; Biology; Genetics","retraction":null,"screen_n_in":null,"score":{"opus":0.05262389046321067,"gpt":0.3617774958511126,"spread":0.3091536053879019,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.001216924,0.001055563,0.002950422,0.0004368294,0.0002504525,0.000134759,0.0006823679,0.0008967265,0.0002791345],"category_scores_gemma":[0.0002835261,0.0007228065,0.001288382,0.0006024166,0.0001432672,0.0001314168,0.0001725256,0.00210843,0.0006750755],"about_ca_system_candidate":true,"about_ca_system_consensus":true,"about_ca_system_score_codex":0.1282837,"about_ca_system_score_gemma":0.04988622,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0006013376,"about_ca_topic_score_gemma":0.000153583,"domain_scores_codex":[0.9950126,0.0004024601,0.001595222,0.001303146,0.0006447648,0.001041804],"domain_scores_gemma":[0.9949392,0.001639773,0.001186281,0.001900113,0.0001337283,0.000200911],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.00007772046,0.00005609993,0.0002711295,0.02318555,0.0006182899,0.00003613306,0.00004432581,0.0007755064,0.00001354703,0.0001542129,0.00110373,0.9736637],"study_design_scores_gemma":[0.007338905,0.0004160585,0.0004967458,0.01255383,0.00404287,0.00005434726,0.00002163409,0.007550501,0.000007090841,0.00006049665,0.9667875,0.0006700674],"study_design_candidate":"design_other","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.0008886761,0.9842914,0.001363216,0.0001265257,0.0007751115,0.01029964,0.0001575101,0.0001602387,0.001937663],"genre_scores_gemma":[0.0006414769,0.9870182,0.003526612,0.0002874838,0.001136255,0.002640038,0.002623463,0.0003154302,0.001811034],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.9729937,"threshold_uncertainty_score":0.9995223,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2169508471","doi":"10.1200/jco.2002.06.077","title":"Long-Term Medical Outcomes and Quality-of-Life Assessment of Patients With Chronic Myeloid Leukemia Followed at Least 10 Years After Allogeneic Bone Marrow Transplantation","year":2002,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":148,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Quality of life (healthcare); Population; Myeloid leukemia; Transplantation; Internal medicine; Bone marrow; Leukemia; Surgery","retraction":null,"screen_n_in":null,"score":{"opus":0.06492735229229302,"gpt":0.408487949971739,"spread":0.343560597679446,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.001730365,0.0002264045,0.002178961,0.0001539931,0.00002531709,0.000004003241,0.0001490666,0.0004968145,0.002368749],"category_scores_gemma":[0.0009302687,0.0001546447,0.0004359527,0.0001122201,0.0004394855,0.0001080831,0.00005700332,0.0006454993,0.00001054857],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001420846,"about_ca_system_score_gemma":0.002820646,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00002754992,"about_ca_topic_score_gemma":0.0004659151,"domain_scores_codex":[0.9946032,0.0005116609,0.003108356,0.0002747549,0.001219,0.0002830894],"domain_scores_gemma":[0.9950178,0.001587746,0.002250351,0.0002633179,0.0002936774,0.0005871609],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.005812877,0.001527007,0.9631491,0.000294839,0.001021642,0.0006035955,0.00009181684,0.000007551117,0.00008318647,0.000005961252,0.0001502559,0.02725215],"study_design_scores_gemma":[0.04297557,0.008572742,0.9466373,0.0002999321,0.000785968,0.0001165801,0.000007800917,0.00005050783,0.00002306355,0.000002861597,0.0004048191,0.0001228588],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9971133,0.0009924077,0.00006530927,0.0008575366,0.0003666493,0.0003290222,0.00002175033,0.000006686886,0.0002473503],"genre_scores_gemma":[0.9954217,0.002171516,0.001220511,0.0004886701,0.0002040772,0.000009041594,0.00002630661,0.00002707718,0.0004310685],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.0371627,"threshold_uncertainty_score":0.9985432,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2029310284","doi":"10.1592/phco.24.16.1508.50958","title":"The Influence of St. John's Wort on the Pharmacokinetics and Protein Binding of Imatinib Mesylate","year":2004,"lang":"en","type":"article","venue":"Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":148,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":false,"ca_fund":false,"ca_venue":false,"about_ca":true},"ca_institutions":"","funders":"National Institute of General Medical Sciences","keywords":"Imatinib mesylate; Pharmacokinetics; Pharmacology; Mesylate; Medicine; Chemistry; Imatinib; Internal medicine","retraction":null,"screen_n_in":null,"score":{"opus":0.01955758906830467,"gpt":0.3302328160462573,"spread":0.3106752269779526,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002123914,0.0003164403,0.000531621,0.0001557405,0.0004872839,0.00001924063,0.0004479905,0.00006213161,0.0002234774],"category_scores_gemma":[0.00002308876,0.0001458383,0.0001536988,0.000232222,0.0009759882,0.0001225538,0.00004840332,0.0007741206,0.000001488692],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001203829,"about_ca_system_score_gemma":0.0002398303,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00002385251,"about_ca_topic_score_gemma":0.000002165061,"domain_scores_codex":[0.9976433,0.0005415668,0.000848921,0.0001736851,0.0004533135,0.0003392114],"domain_scores_gemma":[0.9974723,0.0008264803,0.00108543,0.0002401728,0.0002427744,0.0001328174],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.004885979,0.000424936,0.0007909572,0.0000535194,0.001406727,0.0000291123,0.003384302,0.0004592862,0.9815012,0.0002965744,0.001088212,0.005679174],"study_design_scores_gemma":[0.0238727,0.001779394,0.003050285,0.0002688938,0.0005186535,0.0002794979,0.0003479025,0.0000615869,0.9608473,0.001478603,0.007313252,0.0001818913],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9822388,0.009139108,0.000006176139,0.00715483,0.0001724166,0.001148415,0.00001194474,0.00001232505,0.000116028],"genre_scores_gemma":[0.9622534,0.03533251,0.00005740247,0.001898749,0.000215517,0.00002725893,8.912565e-7,0.00003920269,0.000175101],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.0261934,"threshold_uncertainty_score":0.5947115,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null}]}